var title_f17_41_18064="CRP, cholesterol, and future CV event risk in women";
var content_f17_41_18064=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62229&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62229&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    C-reactive protein predicts cardiovascular events in healthy postmenopausal women",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 341px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Among 28,263 postmenopausal women enrolled in the Women's Health study, C-reactive protein (CRP) was a significant predictor of cardiovascular events; the relative risk of events for women in the highest as compared with the lowest quartile for this marker was 4.4. Prediction models that incorporated CRP in addition to lipids were significantly better at predicting risk than models based on lipid levels alone (P &lt;0.001).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Ridker PM, Hennekens CH, Buring JE, Rifai N. N Engl J Med 2000; 342:836.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_41_18064=[""].join("\n");
var outline_f17_41_18064=null;
var title_f17_41_18065="Optical coherence tomograph";
var content_f17_41_18065=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F53309&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F53309&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Optical coherence tomograph depicting macular edema secondary to branch retinal vein occlusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 174px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Used to assess progression of retinal vein occlusion or response to treatment.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_41_18065=[""].join("\n");
var outline_f17_41_18065=null;
var title_f17_41_18066="Glomus tumor excision";
var content_f17_41_18066=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86591&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86591&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Excision of subungual glomus tumor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Phoebe Rich, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_41_18066=[""].join("\n");
var outline_f17_41_18066=null;
var title_f17_41_18067="Irritant contact dermatitis acute";
var content_f17_41_18067=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F61579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F61579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 527px\">",
"   <div class=\"ttl\">",
"    Acute irritant contact dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 507px; height: 419px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Paederus dermatitis. Acute contact dermatitis may occur after accidental exposure to an insect belonging to the genus Paederu, common in the tropical regions. The insect does not sting or bite, but accidental crushing may release its hemolymph that contains paederin, a potent vesicant.",
"    <br>",
"     (A) Well-defined erythematous patches with central hyperpigmentation and vesicles in a kissing lesion fashion. (Courtesy of Kulthanan K Siriraj Hospital, Mahidol University, Bangkok, Thailand.)",
"     <br>",
"      (B) Well-defined linear erythematous patch with central vesicles and pustules. (Courtesy of Wanitphakdeedecha R Siriraj Hospital, Mahidol University, Bangkok, Thailand.)",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_41_18067=[""].join("\n");
var outline_f17_41_18067=null;
var title_f17_41_18068="Can therapy be discontinued in well-controlled hypertension?";
var content_f17_41_18068=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Can therapy be discontinued in well-controlled hypertension?",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/41/18068/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/41/18068/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/41/18068/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/41/18068/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/41/18068/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/41/18068/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/41/18068/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with mild hypertension who are well controlled for at least one year, it may be possible to gradually diminish or discontinue antihypertensive therapy once [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18068/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. In a review of all published series of planned withdrawal, 42 percent of selected patients with mild hypertension",
"    <span class=\"nowrap\">",
"     (140-149/90-95",
"    </span>",
"    mmHg) were found to remain normotensive for 12 months or longer off medication [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18068/abstract/1\">",
"     1",
"    </a>",
"    ]. In a more heterogeneous group of well-controlled hypertensives, only 18 percent remained normotensive after stopping therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18068/abstract/4\">",
"     4",
"    </a>",
"    ]. Patients who were more likely to tolerate cessation of antihypertensive therapy were those with milder hypertension, on fewer and lower doses of antihypertensive medications, and adherent to lifestyle modifications (eg, weight loss and sodium restriction). These findings suggest that full withdrawal may not be possible in patients on multiple drugs, but it may be possible to more gradually taper antihypertensive doses and agents [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18068/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The value of stopping successful drug therapy is uncertain, however lower doses are associated with a lower incidence of drug-induced side effects. It seems reasonable to reduce the dose in well-controlled patients, and withdraw if tolerated, with continued close surveillance of the BP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of persistent normotension with less intensive drug treatment is incompletely understood. Long-term blood pressure control may reverse hypertension-induced arteriolar hyperplasia thereby reducing vascular resistance directly and by reducing the sensitivity to vasoconstrictors such as angiotensin II and norepinephrine [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18068/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An alternate explanation was suggested by the Medical Research Council trial, which studied this issue in a controlled fashion [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18068/abstract/2\">",
"     2",
"    </a>",
"    ]. Thiazide or beta blocker therapy was either continued or switched to placebo after five to six years of normotension. Within nine to twelve months, the patients switched to placebo had a rise in blood pressure to a level equivalent to that in a separate, mostly nontreated placebo group (",
"    <a class=\"graphic graphic_figure graphicRef69497 \" href=\"UTD.htm?7/4/7232\">",
"     figure 1",
"    </a>",
"    ). However, up to 45 percent of patients in both groups were normotensive.",
"   </p>",
"   <p>",
"    These findings suggest that effective therapy may not alter the course of the disease, but that many patients being treated for mild hypertension are in fact normotensive or become normotensive by compliance with nonpharmacologic therapies. Several factors may contribute to this effect, particularly initial mislabeling and dietary modification. In addition, the ability to lower drug dosage in many patients may be due to the initial use of excessive dosing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mislabeling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients who are at first diagnosed as having mild hypertension are actually normotensive, with the elevation in blood pressure representing an acute stress response induced by visiting the physician. This phenomenon, called \"white-coat\" hypertension, illustrates the importance of repeated blood pressure measurements over several months in the office or, preferably, by multiple home measurements before considering an asymptomatic patient with no end-organ damage to be truly hypertensive. Sequential studies have shown that the BP drops by an average of 10 to 15 mmHg between the first and third office visits in newly diagnosed patients with mild hypertension, with a stable value not being achieved until more than six visits in some cases [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18068/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7113?source=see_link\">",
"     \"Ambulatory blood pressure monitoring and white coat hypertension in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43080?source=see_link\">",
"     \"Blood pressure measurement in the diagnosis and management of hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Dietary modification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are initially hypertensive can, with dietary modification alone, lower their BP into the normal range. . The triad of dietary sodium restriction, weight reduction in the obese, and avoidance of excess alcohol intake may be particularly important when step-down therapy is being considered [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18068/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. Persistent normotension following drug withdrawal may be most likely among nonobese patients who restrict sodium, and overweight patients who lose weight [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18068/abstract/7\">",
"     7",
"    </a>",
"    ]. One study, for example, evaluated the effect of these lifestyle changes following the discontinuation of antihypertensive medications after several years of excellent control. At four years, 39 percent of patients with dietary modification remained normotensive, compared to less than 5 percent of a control group (",
"    <a class=\"graphic graphic_figure graphicRef71815 \" href=\"UTD.htm?30/17/31005\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18068/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42679?source=see_link\">",
"     \"Diet in the treatment and prevention of hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24120?source=see_link\">",
"     \"Salt intake, salt restriction, and essential hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34630?source=see_link\">",
"     \"Obesity and weight reduction in hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Excessive doses",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is now clear that previous dosing recommendations for many antihypertensive drugs were too high, leading to an increased incidence of side effects while producing little if any further reduction in BP. In many patients treated with 50 to 100 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    , for example, lowering the daily dose to 50, 25, and even 12.5 mg can be achieved without loss of blood pressure control [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18068/abstract/3,11\">",
"     3,11",
"    </a>",
"    ]. Furthermore, 12.5 or 25 mg of hydrochlorothiazide (or its equivalent) as initial therapy is often as effective as 50 to 100 mg (",
"    <a class=\"graphic graphic_figure graphicRef61248 \" href=\"UTD.htm?18/24/18829\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18068/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although there is often a greater diuresis with the higher dose, the ensuing rise in renin and therefore angiotensin II leads to an increase in vascular resistance that may counteract the fall in blood volume. Low-dose therapy also minimizes the incidence of hypokalemia, hyperuricemia, and mild elevations in the plasma cholesterol and glucose concentrations (",
"    <a class=\"graphic graphic_figure graphicRef69912 \" href=\"UTD.htm?37/49/38685\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18068/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/63/15350?source=see_link\">",
"     \"Use of thiazide diuretics in patients with primary hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     WITHDRAWAL SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;One last point must be emphasized. Abrupt cessation of therapy with a short-acting beta blocker (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    ) or the short-acting alpha-2-agonist",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    can lead to a potentially fatal withdrawal syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18068/abstract/14\">",
"     14",
"    </a>",
"    ]. This syndrome is characterized by increased sympathetic activity (due to adrenergic receptor upregulation during the period of decreased sympathetic activity), rebound hypertension, and possible accelerated angina or myocardial infarction. Gradual discontinuation of these agents over a period of weeks should prevent this problem. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1827?source=see_link\">",
"     \"Withdrawal syndromes with antihypertensive therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with mild hypertension",
"      <span class=\"nowrap\">",
"       (140-149/90-95",
"      </span>",
"      mmHg) who are well controlled for at least one year, it may be possible to gradually diminish or discontinue antihypertensive therapy. Patients who are more likely to tolerate cessation of antihypertensive therapy are those with milder hypertension, on fewer and lower doses of antihypertensive medications, and adherent to lifestyle modifications such as weight loss and sodium restriction. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mechanism of persistent normotension with less intensive drug treatment is not completely understood. Long-term blood pressure control may reverse hypertension-induced arteriolar hyperplasia that contributes to the rise in blood pressure. Alternatively, many patients being treated for mild hypertension may have had \"white-coat\" hypertension or have successfully lowered their BP into the normal range with dietary modification. In addition, previous dosing recommendations for many antihypertensive drugs were too high, allowing the step-down of medication. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Abrupt cessation of therapy with a short-acting beta blocker or the short-acting alpha-2-agonist",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      can lead to a potentially fatal withdrawal syndrome. This syndrome is characterized by increased sympathetic activity, rebound hypertension, and possible accelerated angina or myocardial infarction. Gradual discontinuation of these agents over a period of weeks should prevent this problem. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Withdrawal syndromes'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1827?source=see_link\">",
"       \"Withdrawal syndromes with antihypertensive therapy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18068/abstract/1\">",
"      Schmieder RE, Rockstroh JK, Messerli FH. Antihypertensive therapy. To stop or not to stop? JAMA 1991; 265:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18068/abstract/2\">",
"      Course of blood pressure in mild hypertensives after withdrawal of long term antihypertensive treatment. Medical Research Council Working Party on Mild Hypertension. Br Med J (Clin Res Ed) 1986; 293:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18068/abstract/3\">",
"      Freis ED, Thomas JR, Fisher SG, et al. Effects of reduction in drugs or dosage after long-term control of systemic hypertension. Am J Cardiol 1989; 63:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18068/abstract/4\">",
"      Nelson MR, Reid CM, Krum H, et al. Short-term predictors of maintenance of normotension after withdrawal of antihypertensive drugs in the second Australian National Blood Pressure Study (ANBP2). Am J Hypertens 2003; 16:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18068/abstract/5\">",
"      Christensen KL, Mulvany MJ. Vasodilatation, not hypotension, improves resistance vessel design during treatment of essential hypertension: a literature survey. J Hypertens 2001; 19:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18068/abstract/6\">",
"      Hartley RM, Velez R, Morris RW, et al. Confirming the diagnosis of mild hypertension. Br Med J (Clin Res Ed) 1983; 286:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18068/abstract/7\">",
"      Langford HG, Blaufox MD, Oberman A, et al. Dietary therapy slows the return of hypertension after stopping prolonged medication. JAMA 1985; 253:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18068/abstract/8\">",
"      Stamler R, Stamler J, Grimm R, et al. Nutritional therapy for high blood pressure. Final report of a four-year randomized controlled trial--the Hypertension Control Program. JAMA 1987; 257:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18068/abstract/9\">",
"      Nelson M, Reid C, Krum H, McNeil J. A systematic review of predictors of maintenance of normotension after withdrawal of antihypertensive drugs. Am J Hypertens 2001; 14:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18068/abstract/10\">",
"      Appel LJ, Espeland MA, Easter L, et al. Effects of reduced sodium intake on hypertension control in older individuals: results from the Trial of Nonpharmacologic Interventions in the Elderly (TONE). Arch Intern Med 2001; 161:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18068/abstract/11\">",
"      Finnerty FA Jr. Stepped-down therapy versus intermittent therapy in systemic hypertension. Am J Cardiol 1990; 66:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18068/abstract/12\">",
"      Carlsen JE, K&oslash;ber L, Torp-Pedersen C, Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ 1990; 300:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18068/abstract/13\">",
"      Johnston GD, Wilson R, McDermott BJ, et al. Low-dose cyclopenthiazide in the treatment of hypertension: a one-year community-based study. Q J Med 1991; 78:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18068/abstract/14\">",
"      Houston MC. Abrupt cessation of treatment in hypertension: consideration of clinical features, mechanisms, prevention and management of the discontinuation syndrome. Am Heart J 1981; 102:415.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3864 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-5115C1355F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_41_18068=[""].join("\n");
var outline_f17_41_18068=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mislabeling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Dietary modification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Excessive doses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      WITHDRAWAL SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3864\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3864|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/4/7232\" title=\"figure 1\">",
"      Rapid rise in blood pressure after discontinuation of chronic antihypertensive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/17/31005\" title=\"figure 2\">",
"      Ability of dietary modification to maintain normotension after discontinuation of chronic antihypertensive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/24/18829\" title=\"figure 3\">",
"      Antihypertensive dose-response to thiazide therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/49/38685\" title=\"figure 4\">",
"      Thiazide side effects and dose",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7113?source=related_link\">",
"      Ambulatory blood pressure monitoring and white coat hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43080?source=related_link\">",
"      Blood pressure measurement in the diagnosis and management of hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42679?source=related_link\">",
"      Diet in the treatment and prevention of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34630?source=related_link\">",
"      Obesity and weight reduction in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24120?source=related_link\">",
"      Salt intake, salt restriction, and essential hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/63/15350?source=related_link\">",
"      Use of thiazide diuretics in patients with primary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1827?source=related_link\">",
"      Withdrawal syndromes with antihypertensive therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_41_18069="Gottrons sign 2";
var content_f17_41_18069=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Gottron's sign",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 328px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hyperpigmented patches are present on the dorsal hand.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_41_18069=[""].join("\n");
var outline_f17_41_18069=null;
var title_f17_41_18070="Insulin detemir: Pediatric drug information";
var content_f17_41_18070=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Insulin detemir: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?24/49/25367?source=see_link\">",
"    see \"Insulin detemir: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?6/8/6277?source=see_link\">",
"    see \"Insulin detemir: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2110562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Levemir&reg;;",
"     </li>",
"     <li>",
"      Levemir&reg; FlexPen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2186123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Levemir&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F2983770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidiabetic Agent, Parenteral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Insulin, Intermediate-Acting",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F2983801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/49/25367?source=see_link\">",
"      see \"Insulin detemir: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Insulin detemir is an intermediate-acting insulin administered by SubQ injection. When compared to insulin NPH, insulin detemir has slower, more prolonged absorption; duration of activity is dose-dependent. Insulin detemir may be given once or twice daily when used as the basal insulin component of therapy. Changing the basal insulin component from another insulin to insulin detemir can be done on a unit-to-unit basis. Insulin requirements vary dramatically between patients and dictate frequent monitoring and close medical supervision. See Insulin Regular for additional information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      General insulin dosing:",
"     </b>",
"     <b>",
"      Type 1 diabetes mellitus:",
"     </b>",
"     Children, Adolescents, and Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Multiple daily doses are utilized and guided by blood glucose monitoring. Combinations of insulin formulations are commonly used. The daily doses presented below are expressed as the",
"     <b>",
"      total units/kg/day of all insulin formulations combined",
"     </b>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Usual maintenance range:",
"     </b>",
"     SubQ: 0.5-1 unit/kg/day in divided doses. An estimate of anticipated needs may be based on body weight and/or activity factors as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adolescents: May require &le;1.2 units/kg/day during growth spurts",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Nonobese: 0.4-0.6 units/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Obese: 0.8-1.2 units/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Adjustment of dose:",
"     </b>",
"     Dosage must be titrated to achieve glucose control and avoid hypoglycemia. Adjust dose to maintain premeal and bedtime glucose in target range. Since combinations of agents are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Insulin detemir-specific dosing:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Type 1 diabetes mellitus:",
"     </b>",
"     Children &ge;2 years, Adolescents, and Adults: SubQ: Initial dose: Approximately one-third of the total daily insulin requirement; a rapid-acting or short-acting insulin should also be used. If administered once daily, doses are generally administered with evening meals or at bedtime.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Conversion from insulin glargine or NPH insulin:",
"     </i>",
"     Children &ge;2 years, Adolescents, and Adults: SubQ: May be substituted on an equivalent unit-per-unit basis; in one Type 2 diabetes clinical trial, higher doses of insulin detemir were required than insulin NPH.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Type 2 diabetes mellitus:",
"     </b>",
"     Adults: SubQ: Initial basal insulin dose: 10 units (",
"     <b>",
"      or",
"     </b>",
"     0.1-0.2 units/kg) once daily in the evening; may also administer total daily dose in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <i>",
"      Conversion from insulin glargine or NPH insulin:",
"     </i>",
"     Children &ge;2 years, Adolescents, and Adults: SubQ: May be substituted on an equivalent unit-per-unit basis; in one Type 2 diabetes clinical trial, higher doses of insulin detemir were required than insulin NPH",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Insulin requirements are reduced due to changes in insulin clearance or metabolism",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2104225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Levemir&reg;: 100 units/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Levemir&reg; FlexPen&reg;: 100 units/mL (3 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F2110321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2983802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Parenteral: SubQ: Administer into the thighs, deltoids, or abdomen, with sites rotated. Cold injections should be avoided.",
"     <b>",
"      Not for I.V. infusion",
"     </b>",
"     or use in insulin infusion pumps. Do not use if solution is viscous or cloudy; use only if clear and colorless with no visible particles. May not be diluted or mixed with other insulins or solutions. When treated once daily, administer with evening meal or at bedtime. When treated twice daily, administer evening dose with evening meal, at bedtime, or 12 hours following the morning dose.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F2110190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Insulin aspart, insulin glargine, insulin glulisine, insulin lispro, insulin NPH, insulin regular.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F2983778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store unopened vials and prefilled pens between 2&deg;C and 8&deg;C (36&deg;F to 46&deg;F) until the expiration date or at room temperature &lt;30&deg;C (&lt;86&deg;F) for 42 days; do not freeze; keep away from heat and sunlight. Once punctured (in use), vials may be stored in refrigerator or at room temperature &lt;30&deg;C (&lt;86&deg;F); use within 42 days (includes days stored at room temperature for unopened vials, if applicable). Prefilled pens that have been punctured (in use) should be stored at temperatures &lt;30&deg;C (&lt;86&deg;F) and used within 42 days (includes days stored at room temperature for unused pens, if applicable); do not freeze or refrigerate. Do not store with needle in place. Do not dilute or mix with other insulins or solutions.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2983771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of type 1 diabetes mellitus (insulin dependent, IDDM) to improve glycemic control (FDA approved in ages &ge;2 years and adults); treatment of type 2 diabetes mellitus (noninsulin dependent, NIDDM) to improve glycemic control (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2110182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"       <b>",
"        <i>",
"         Due to the number of insulin preparations, it is essential to identify/clarify the type of insulin to be used.",
"        </i>",
"       </b>",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Insulin detemir is a clear solution, but it is NOT intended for I.V. or I.M. administration.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cross-contamination may occur if insulin pens are shared among multiple patients. Steps should be taken to prohibit sharing of insulin pens.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F2110188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Primarily symptoms of hypoglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Pallor, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fatigue, headache, hypothermia, loss of consciousness, mental confusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Redness, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia, hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Hunger, nausea, numbness of mouth",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Atrophy or hypertrophy of SubQ fat tissue; edema, itching, pain or warmth at injection site; stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle weakness, paresthesia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Transient presbyopia or blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, diaphoresis, local and/or systemic hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2983773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to insulin detemir or any component; hypoglycemia",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F2984232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution  in patients with renal impairment; monitor closely; dosage adjustment may be required.  Use with caution  in patient with hepatic impairment; monitor closely; dosage adjustment may be required. Use with caution in patients at risk for hypokalemia (eg, concurrent loop diuretic); insulin causes a shift of potassium from the extracellular space to the intracellular space possibly causing hypokalemia; higher risk with intravenous insulin use. Untreated hypokalemia may result in respiratory paralysis, ventricular arrhythmia, and even death; monitor serum potassium and supplement potassium when necessary.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2983774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Insulin detemir should not be used for management of diabetic ketoacidosis; a short-acting insulin is recommended. Hypoglycemia is the most common adverse effect of insulin. The timing of hypoglycemia differs among various insulin formulations. Hypoglycemia may result from increased work or exercise without eating; use of long-acting insulin preparations (eg, insulin detemir) may delay recovery from hypoglycemia. Profound and prolonged episodes of hypoglycemia may result in convulsions, unconsciousness, temporary or permanent brain damage, or even death. Insulin requirements may be altered during illness, emotional disturbances, or other stressors. Any change of insulin should be made cautiously; changing manufacturers, type, and/or method of manufacture may result in the need for a change of dosage. Although insulin detemir is a clear solution; it is",
"     <b>",
"      NOT",
"     </b>",
"     intended for I.V. or I.M. administration or for use in insulin infusion pumps. Severe allergic reactions, including anaphylaxis, may occur with insulin products.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F2110324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F2110323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents (Thiazolidinedione): Insulin may enhance the fluid-retaining effect of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the hypoglycemic effect of Insulin.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Edetate CALCIUM Disodium: May enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Edetate Disodium: May enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Insulin may enhance the hyperglycemic effect of Quinolone Antibiotics. Insulin may enhance the hypoglycemic effect of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F2983777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Use caution with chromium, garlic, gymnema (may increase hypoglycemia).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F2110568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2110569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose-related adverse events were observed in animal reproduction studies. Limited information is available related to the use of insulin detemir in pregnancy. Maternal hyperglycemia can be associated with adverse effects in the fetus, including macrosomia, neonatal hyperglycemia, and hyperbilirubinemia; the risk of congenital malformations is increased when the Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     is &gt;1% above the normal range. Insulin requirements tend to fall during the first trimester of pregnancy and increase in the later trimesters, peaking at 28-32 weeks of gestation. Following delivery, insulin requirements decrease rapidly. Diabetes can also be associated with adverse effects in the mother. Poorly treated diabetes may cause end-organ damage that may in turn negatively affect obstetric outcomes. Physiologic glucose levels should be maintained prior to and during pregnancy to decrease the risk of adverse events in the fetus and the mother. Insulin is the drug of choice for the control of diabetes mellitus during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2983803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Urine sugar and acetone, serum glucose, electrolytes, Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     , lipid profile",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F2983804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Plasma Blood Glucose and Hgb A",
"      <sub>",
"       1C",
"      </sub>",
"      Goals for Type 1 Diabetes (ADA, 2013): Note:",
"     </b>",
"     Goals should be individualized based on individual needs/circumstances (eg, patients who experience severe hypoglycemia, patients with hypoglycemic unawareness); lower goals may be reasonable if they can be achieved without excessive hypoglycemia.",
"     <b>",
"      Note:",
"     </b>",
"     Postprandial blood glucose should be measured when there is a discrepancy between preprandial blood glucose concentrations and Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     values and to help assess glycemia for patients who receive basal/bolus regimens. It is usually drawn 1-2 hours after starting meal and is considered to be the \"peak.\"",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toddlers/Preschoolers (0-6 years):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Preprandial glucose: 100-180 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Bedtime/overnight glucose:  110-200 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     : &lt;8.5%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     School age (6-12 years):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Preprandial glucose: 90-180 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Bedtime/overnight glucose: 100-180 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     : &lt;8%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adolescents/Young adults (13-19 years):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Preprandial glucose: 90-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Bedtime/overnight glucose: 90-150 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     : &lt;7.5%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults, nonpregnant:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Preprandial glucose: 70-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Postprandial glucose: &lt;180 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     : &lt;7%",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2983779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Insulin acts via specific membrane-bound receptors on target tissues to regulate metabolism of carbohydrate, protein, and fats. Insulin facilitates entry of glucose into muscle, adipose, and other tissues via hexose transporters, including GLUT4. Insulin stimulates the cellular uptake of amino acids and increases cellular permeability to several ions, including potassium, magnesium, and phosphate. By activating sodium-potassium ATPases, insulin promotes the intracellular movement of potassium.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Target organs for insulin include the liver, skeletal muscle, and adipose tissue. Within the liver, insulin stimulates hepatic glycogen synthesis through the activation of the enzymes hexokinase, phosphofructokinase, and glycogen synthase as well as the inhibition of glucose-6 phosphatase. Insulin promotes hepatic synthesis of fatty acids, which are released into the circulation as lipoproteins. Skeletal muscle effects of insulin include increased protein synthesis and increased glycogen synthesis. Within adipose tissue, insulin stimulates the processing of circulating lipoproteins to provide free fatty acids, facilitating triglyceride synthesis and storage by adipocytes. Insulin also directly inhibits the hydrolysis of triglycerides.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Normally secreted by the pancreas, insulin products are manufactured for pharmacologic use through recombinant DNA technology using either",
"     <i>",
"      E. coli",
"     </i>",
"     or",
"     <i>",
"      Saccharomyces cerevisiae",
"     </i>",
"     . Insulins are categorized based on promptness and duration of effect, including rapid-, short-, intermediate-, and long-acting insulins. The product labeling identifies this product as a long-acting insulin analog; however, its pharmacodynamic characteristics and dosing are typical of intermediate insulin forms. In some patients, or at higher dosages, it may have a duration of action approaching long-acting insulins.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F2984263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 3-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: 3-9 hours (Plank, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: 6-23 hours (dose dependent);",
"     <b>",
"      Note:",
"     </b>",
"     Duration is dose-dependent. At lower dosages (0.1-0.2 units/kg), mean duration is variable (5.7-12.1 hours). At 0.4 units/kg, the mean duration was 19.9 hours. At high dosages (&ge;0.8 units/kg) the duration is longer and less variable (mean: 22-23 hours) (Plank, 2005).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2983780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.1 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;98% (albumin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: SubQ: 5-7 hours (dose dependent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration: 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F2983805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/8/6277?source=see_link\">",
"      see \"Insulin detemir: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not take any new medication during therapy unless approved by healthcare provider. This medication is used to control diabetes; it is not a cure. It is imperative to follow other components of prescribed treatment (eg, diet and exercise regimen). Take exactly as directed. Do not change dose or discontinue unless advised by healthcare provider. If you experience hypoglycemic reaction, contact healthcare provider immediately. Always carry quick source of sugar with you. Monitor glucose levels as directed by healthcare provider. Report adverse side effects, including chest pain or palpitations; persistent fatigue, confusion, headache; skin rash or redness; numbness of mouth, lips, or tongue; muscle weakness or tremors; vision changes; respiratory difficulty; or nausea, vomiting, or flu-like symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F14455319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Division of daily insulin requirement (\"conventional therapy\"):",
"     </b>",
"     Generally, 50% to 75% of the daily insulin dose is given as an intermediate-acting (eg, insulin detemir) or a long-acting form of insulin (in 1-2 daily injections). The remaining portion of the 24-hour insulin requirement is divided and administered as either regular insulin or a rapid-acting form of insulin at the same time before breakfast and dinner.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Division of daily insulin requirement (\"intensive therapy\"):",
"     </b>",
"     Basal insulin delivery with 1 or 2 doses of intermediate-acting (eg, insulin detemir) or long-acting insulin formulations superimposed with doses of rapid- or very rapid-acting insulin formulations 3 or more times daily.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12588 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-199.231.185.123-EFBF5593C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_41_18070=[""].join("\n");
var outline_f17_41_18070=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110562\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2186123\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2983770\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2983801\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104225\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110321\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2983802\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110190\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2983778\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2983771\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110182\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110188\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2983773\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984232\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2983774\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110324\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110323\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2983777\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110568\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110569\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2983803\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2983804\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2983779\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2984263\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2983780\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2983805\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14455319\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12588\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12588|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/49/25367?source=related_link\">",
"      Insulin detemir: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/8/6277?source=related_link\">",
"      Insulin detemir: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_41_18071="Pectus excavatum: Etiology and evaluation";
var content_f17_41_18071=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pectus excavatum: Etiology and evaluation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/41/18071/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/41/18071/contributors\">",
"     Oscar H Mayer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/41/18071/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/41/18071/contributors\">",
"     Gregory Redding, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/41/18071/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/41/18071/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/41/18071/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pectus excavatum (PE), or \"funnel chest\", is a deformity of the chest wall characterized by a sternal depression typically beginning over the midportion of the manubrium and progressing inward through the xiphoid process.",
"   </p>",
"   <p>",
"    The clinical significance of PE depends on three issues:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severity of the chest wall defect",
"     </li>",
"     <li>",
"      Cardiopulmonary morbidity",
"     </li>",
"     <li>",
"      Psychosocial impact of the defect, and its appearance on the patient",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite decades of experience with surgical and nonsurgical treatment, and efforts to quantify outcomes in each of these areas, the decision of when and how to treat PE remains controversial. These issues are discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21704?source=see_link\">",
"     \"Pectus excavatum: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will discuss the epidemiology, clinical features, and evaluation of PE.",
"   </p>",
"   <p>",
"    The diagnosis and treatment of pectus carinatum and other chest wall deformities are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25207?source=see_link\">",
"     \"Pectus carinatum\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24490?source=see_link\">",
"     \"Diseases of the chest wall\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;PE accounts for 90 percent of anterior chest wall disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/1\">",
"     1",
"    </a>",
"    ]. The incidence of pectus excavatum is 1 in every 400 to 1000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It is three to five times more prevalent in males than females.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;While there is no consensus for what causes PE, there have been a number of hypotheses, ranging from disproportionate muscular force putting abnormal stress and strain on the sternum and costal cartilages, to defective cartilage structure and growth, or combinations thereof.",
"   </p>",
"   <p>",
"    An early theory that PE is caused by abnormal diaphragmatic connections was discarded, because surgical interventions to release the central tendon and substernal ligament in early childhood were not effective [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21704?source=see_link&amp;anchor=H5#H5\">",
"     \"Pectus excavatum: Treatment\", section on 'Historical approaches'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PE is usually sporadic [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/1\">",
"     1",
"    </a>",
"    ], but it has been associated with connective tissue disorders (particularly Marfan syndrome, Ehlers Danlos syndrome, and osteogenesis imperfecta) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/4\">",
"     4",
"    </a>",
"    ] and neuromuscular disease (eg, spinal muscular atrophy). It also can be seen in a variety of other genetic conditions, including Noonan syndrome, Turner syndrome, and multiple endocrine neoplasia type 2b [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=see_link\">",
"     \"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The increased prevalence of PE in connective tissue disorders suggests the possibility that it is caused by abnormal cartilage development [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/6\">",
"     6",
"    </a>",
"    ]. In particular, some authors have hypothesized that the deformity is caused by abnormalities of cartilage remodeling due to an imbalance between cartilage growth-promoting and growth-inhibiting genes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/1\">",
"     1",
"    </a>",
"    ]. Genetic contributors to PE seem likely, and familial patterns of inheritance have occasionally been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Several different genes affecting cartilage growth are associated with syndromic causes of PE (eg, fibrillin1 gene in Marfan syndrome and genes in the RasMAPK pathway in Noonan syndrome). However, no specific genetic triggers for abnormal cartilage growth in nonsyndromic (isolated) PE have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/9\">",
"     9",
"    </a>",
"    ]. Cartilage samples from patients with pectus excavatum have normal histology [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PE may also occur in response to underlying pulmonary conditions. Patients with a repaired congenital diaphragmatic hernia are prone to PE, presumably because the axis of contraction of the diaphragm is more horizontal than vertical, and therefore pulls the lower edge of the sternum inward [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/6\">",
"     6",
"    </a>",
"    ]. Patients with spinal muscular atrophy type 1 are also prone to developing PE, presumably because the chest wall is highly compliant and unable to resist intrapleural pressure variation during respiration; these forces gradually deform the sternum over time. PE also can occur in children with subglottic stenosis and bronchopulmonary dysplasia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28026?source=see_link\">",
"     \"Congenital diaphragmatic hernia in the neonate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8344?source=see_link\">",
"     \"Spinal muscular atrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"   </p>",
"   <p>",
"    Information on the evolution of untreated PE is based upon limited retrospective data and reports of clinical impressions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. The following observations are generally accepted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      About one third of cases of PE present in infancy [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Spontaneous regression of PE in infancy is rare [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/2\">",
"       2",
"      </a>",
"      ]. The frequency of spontaneous improvement decreases further after one year of age, and no spontaneous improvement can be expected after six years of age.",
"     </li>",
"     <li>",
"      After 12 years of age, the PE deformity worsens in one-third of patients during the adolescent growth spurt, and remains the same in two-thirds [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/10,13\">",
"       10,13",
"      </a>",
"      ]. There are no reliable markers to predict progression.",
"     </li>",
"     <li>",
"      As PE worsens, simple symmetrical lesions may progress to more complex asymmetric deformities [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/13-16\">",
"       13-16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No debilitating physiologic disabilities or deaths have been attributed to PE in children or young adults [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/10\">",
"     10",
"    </a>",
"    ]. In adults, complaints of exercise intolerance are common; no deaths have been attributed to the isolated deformity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cosmetic concerns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concerns about physical appearance are common among patients with PE who seek medical attention [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Female patients are more likely to express concern over their appearance than male patients (68 versus 40 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/17\">",
"     17",
"    </a>",
"    ]. However, there is poor correlation between the severity of PE and concern about appearance [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/17\">",
"     17",
"    </a>",
"    ]. One longitudinal study suggests that cosmetic concerns subside over time: among patients with mild PE who did not undergo surgery, the concern about appearance usually subsided by 18 to 20 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among a large group of patients evaluated for PE, most of whom were in the pediatric age range, the following symptoms were reported [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Exertional intolerance &mdash; 82 percent",
"     </li>",
"     <li>",
"      Chest pain &mdash; 68 percent",
"     </li>",
"     <li>",
"      Poor endurance &mdash; 67 percent",
"     </li>",
"     <li>",
"      Shortness of breath &mdash; 42 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a separate study, similar frequencies of these problems were reported in a group of 50 adults with PE [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/18\">",
"     18",
"    </a>",
"    ]. While young children are less likely to display these symptoms, they may develop during adolescence, sometimes in as little as six months [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with PE should be evaluated to estimate the severity of the deformity, and whether there are associated anomalies.",
"   </p>",
"   <p>",
"    Patients with moderate or severe PE, or with complaints suggesting cardiorespiratory compromise, should be evaluated by computed tomography (CT) to quantify the severity of PE. They should also undergo pulmonary function testing to assess for restrictive lung disease, and exercise testing to assess for cardiopulmonary limitation. If there is significant displacement of the heart or cardiopulmonary limitation, we suggest performing echocardiography and electrocardiography. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Cardiac Function'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For patients not deemed to be candidates for surgical correction after the initial evaluation, it is important to repeat the examination periodically. This is especially important during periods of rapid growth, such as adolescence, because the deformity and associated symptoms may increase markedly [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Natural History'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sternal depression &mdash; The sternal depression can be qualitatively assessed on visual examination (",
"      <a class=\"graphic graphic_picture graphicRef69804 \" href=\"UTD.htm?30/62/31712\">",
"       picture 1",
"      </a>",
"      ). The depression can be measured quantitatively using calipers to compare the distance between the point of maximal sternal depression and the spine, with similar measurements laterally in each mid clavicular line [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/21\">",
"       21",
"      </a>",
"      ]. One author suggested that a difference between the two measurements (the depth of depression) of &gt;2.5 cm constitutes a moderate to severe defect [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/21\">",
"       21",
"      </a>",
"      ]. Caliper measurements can also be useful in assessing asymmetry and describing the chest wall contortion [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Thoracic abnormalities &mdash; In addition to the sternal depression, patients with PE often have a narrowed chest wall diameter and a flat, broad, and kyphotic chest [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/23\">",
"       23",
"      </a>",
"      ]. Between 10 and 39 percent of patients with PE also have associated scoliosis, which may be severe [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/2,6,19,24,25\">",
"       2,6,19,24,25",
"      </a>",
"      ]. Scoliosis may present early or late in the course of pectus excavatum, and it is unclear whether chest wall repair affects the onset or progression of scoliosis.",
"     </li>",
"     <li>",
"      Respiratory function &mdash; Resting tachypnea has been reported by up to 98 percent of patients and can be more prominent in adolescence [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/2\">",
"       2",
"      </a>",
"      ]. Patients with more severe forms of pectus excavatum are much more likely to have reduced aerobic capacity. Although laryngomalacia has been reported in infants with pectus excavatum, upper or lower respiratory abnormalities are uncommon findings on physical exam [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cardiac examination &mdash; Abnormalities of the cardiac examination may be seen in patients with associated syndromes (eg, Noonan or Marfan), because these syndromes are associated with cardiovascular anomalies, but are unusual in patients with isolated PE. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=see_link\">",
"       \"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10537?source=see_link&amp;anchor=H19#H19\">",
"       \"Causes of short stature\", section on 'Noonan syndrome'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with severe PE can have tachycardia due to a reduced stroke volume, depending on the distortion and displacement of the heart [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/22\">",
"     22",
"    </a>",
"    ]. Functional systolic murmurs are heard in about 18 percent of patients, probably due to compression of the left ventricular outflow tract [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/2\">",
"     2",
"    </a>",
"    ]. Mitral valve prolapse has been reported in 7 to 20 percent of patients with pectus excavatum [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/2,4\">",
"     2,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain radiographs in the anteroposterior and lateral planes have limited value in assessing the pectus defect, but they can be useful in evaluating for coincident kyphoscoliosis or lung disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     CT scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT scans are useful to accurately determine the severity of the pectus defect and its impact on the lungs, heart, and large vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/6\">",
"     6",
"    </a>",
"    ]. Three-dimensional reconstructions can be performed to assess the defect from a variety of different angles [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/26\">",
"     26",
"    </a>",
"    ]. The pectus severity index (PSI), also known as the Haller index, describes the depth of the pectus defect by comparing the ratio of the lateral diameter of the chest to the distance between the sternum and spine, at the point of maximal depression (",
"    <a class=\"graphic graphic_figure graphicRef78522 \" href=\"UTD.htm?8/41/8851\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/27\">",
"     27",
"    </a>",
"    ]. A normal chest has a PSI of 2.5 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/28\">",
"     28",
"    </a>",
"    ]. Among patients referred for surgery based on clinical criteria (ie, without consideration of CT scan results), all patients had a PSI of &gt;3.25, whereas patients with PE who were not referred for surgery had PSI &lt;3.25 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other protocols have been developed to assess the pectus defect at different levels through the thorax, evaluating asymmetry by comparing the anteroposterior diameter at each mid axillary line to the lateral diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/29\">",
"     29",
"    </a>",
"    ]. Other indices have been proposed to measure thoracic and cardiac distortion in an effort to quantify the severity of PE and define thresholds for surgical intervention (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82696 \" href=\"UTD.htm?28/8/28800\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Magnetic resonance imaging also has been successfully used for this purpose and has the advantage of avoiding radiation exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pulmonary Function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities on pulmonary function testing are two to three times less common than subjective pulmonary complaints in patients with PE, and the correlation between the two is weak [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/18\">",
"     18",
"    </a>",
"    ]. Forced vital capacity (FVC) is normal in the vast majority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/6,28,33-35\">",
"     6,28,33-35",
"    </a>",
"    ]. Interestingly, the total lung capacity (TLC), residual volume (RV), and",
"    <span class=\"nowrap\">",
"     RV/TLC",
"    </span>",
"    results are more variable [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/1,34,35\">",
"     1,34,35",
"    </a>",
"    ]. However, normal pulmonary function tests do not exclude the possibility of cardiopulmonary limitation during exercise. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Exercise Testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cardiac Function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with PE commonly have cardiac displacement to the left. In one large series of female patients, 68 percent had electrocardiographic evidence of right ventricular strain [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/36\">",
"     36",
"    </a>",
"    ]. Electrocardiographic evidence of right axis deviation and ST segment depression in patients with severe PE usually reflects rotation and compression of the heart rather than an intrinsic myocardial abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Echocardiography has demonstrated subtle right ventricular outflow obstruction and reduced right ventricular systolic function in patients with severe PE [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/37,38\">",
"     37,38",
"    </a>",
"    ], and these measures improve after surgical treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21704?source=see_link&amp;anchor=H8#H8\">",
"     \"Pectus excavatum: Treatment\", section on 'Outcomes'",
"    </a>",
"    .) The cardiac distortion may be associated with conduction abnormalities, such as bundle branch block, which were present in 16 percent of patients in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Exercise Testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;For detecting cardiopulmonary abnormalities, exercise testing is more sensitive than spirometry or thoracic gas volume measurements performed at rest [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/1,41\">",
"     1,41",
"    </a>",
"    ]. This may be because exercise testing evaluates the interplay between the cardiac and pulmonary systems.",
"   </p>",
"   <p>",
"    Exercise testing demonstrates mild impairment in some patients with severe PE, and the degree of impairment correlates with the severity of the defect. This exertional limitation is due to cardiovascular dysfunction rather than ventilatory limitation or physical deconditioning, as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series, patients with PE exhibited mildly reduced maximum oxygen uptake (VO2max 75 percent of predicted) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/28\">",
"       28",
"      </a>",
"      ]. The threshold for lactate accumulation was abnormally low, particularly in patients with severe PE (pectus index &gt;4). Total lung capacity, residual volume, and ventilatory reserve volume were normal.",
"     </li>",
"     <li>",
"      In another series, the increase in tidal volume (Vt),",
"      <span class=\"nowrap\">",
"       Vt/FVC,",
"      </span>",
"      and respiratory rate during exercise were normal, indicating that exercise was not restricted by the chest wall deformity [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      By contrast, a third series found that the",
"      <span class=\"nowrap\">",
"       Vt/FVC",
"      </span>",
"      was lower, and the respiratory rate higher during exercise testing in patients with PE as compared to normal controls, perhaps indicating a higher metabolic cost of breathing in an mechanically inefficient system [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18071/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pectus excavatum (PE), is a deformity of the chest wall characterized by a sternal depression beginning over the midportion of the manubrium and progressing inward toward the xiphoid process.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PE is usually sporadic, but it has been associated with connective tissue disorders, such as Marfan syndrome and Ehlers Danlos syndrome, neuromuscular disease, and a variety of other genetic conditions, including Noonan syndrome and Turner syndrome. The pathogenesis of PE and reasons for these associations are not well established. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PE can be present at birth, and in some cases may resolve. However, it tends to worsen during the rapid growth of adolescence. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Natural History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with PE typically present with cosmetic concerns, but some patients also report exercise intolerance and shortness of breath. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evaluation of a patient with moderate or severe PE includes quantification of the sternal depression using measurements from chest CT scanning (known as the pectus severity index, PSI). A typical candidate for surgery usually has a PSI of &gt;3.25. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Candidates for surgical intervention should undergo electrocardiography and echocardiography, as well as pulmonary function testing and exercise testing, if available. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Lung volumes are typically normal. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Pulmonary Function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Electrocardiography may demonstrate right axis deviation and ST segment depression, which reflects rotation and compression of the heart. Some patients have conduction abnormalities, such as bundle branch block. Echocardiography may demonstrate subtle right ventricular outflow obstruction and reduced right ventricular systolic function in patients with severe PE. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Cardiac Function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exercise testing demonstrates mild impairment in many patients with PE. The impairment correlates with the severity of the defect, and is consistent with cardiovascular dysfunction rather than ventilatory limitation or physical deconditioning. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Exercise Testing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18071/abstract/1\">",
"      Fokin AA, Steuerwald NM, Ahrens WA, Allen KE. Anatomical, histologic, and genetic characteristics of congenital chest wall deformities. Semin Thorac Cardiovasc Surg 2009; 21:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18071/abstract/2\">",
"      Fonkalsrud EW. 912 open pectus excavatum repairs: changing trends, lessons learned: one surgeon's experience. World J Surg 2009; 33:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18071/abstract/3\">",
"      Lester CW. The Surgical Treatment of Funnel Chest. Ann Surg 1946; 123:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18071/abstract/4\">",
"      Williams AM, Crabbe DC. Pectus deformities of the anterior chest wall. Paediatr Respir Rev 2003; 4:237.",
"     </a>",
"    </li>",
"    <li>",
"     Jones, KL. Smith's recognizable patterns of human malformation. In: New Reference, Elsevier, Philadelphia 2006. p.901.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18071/abstract/6\">",
"      Kelly RE Jr. Pectus excavatum: historical background, clinical picture, preoperative evaluation and criteria for operation. Semin Pediatr Surg 2008; 17:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18071/abstract/7\">",
"      Leung AK, Hoo JJ. Familial congenital funnel chest. Am J Med Genet 1987; 26:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18071/abstract/8\">",
"      Creswick HA, Stacey MW, Kelly RE Jr, et al. Family study of the inheritance of pectus excavatum. J Pediatr Surg 2006; 41:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18071/abstract/9\">",
"      Kotzot D, Schwabegger AH. Etiology of chest wall deformities--a genetic review for the treating physician. J Pediatr Surg 2009; 44:2004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18071/abstract/10\">",
"      Humphreys GH 2nd, Jaretzki A 3rd. Pectus excavatum. Late results with and without operation. J Thorac Cardiovasc Surg 1980; 80:686.",
"     </a>",
"    </li>",
"    <li>",
"     Krummel, MT. In: Kendig's Disorders of the Respiratory Tract in Children, 6th ed, WB Saunders 1998. p.287.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18071/abstract/12\">",
"      Haller JA Jr, Loughlin GM. Cardiorespiratory function is significantly improved following corrective surgery for severe pectus excavatum. Proposed treatment guidelines. J Cardiovasc Surg (Torino) 2000; 41:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18071/abstract/13\">",
"      Lacquet LK, Morshuis WJ, Folgering HT. Long-term results after correction of anterior chest wall deformities. J Cardiovasc Surg (Torino) 1998; 39:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18071/abstract/14\">",
"      CHIN EF. Surgery of funnel chest and congenital sternal prominence. Br J Surg 1957; 44:360.",
"     </a>",
"    </li>",
"    <li>",
"     Landolfo KP, Sabiston DC. Surgery of the Chest, 6th ed, Sabiston DC, Spencer FC (Eds), WB Saunders, Philadelphia 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18071/abstract/16\">",
"      Fonkalsrud EW. Current management of pectus excavatum. World J Surg 2003; 27:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18071/abstract/17\">",
"      Kelly RE Jr, Cash TF, Shamberger RC, et al. Surgical repair of pectus excavatum markedly improves body image and perceived ability for physical activity: multicenter study. Pediatrics 2008; 122:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18071/abstract/18\">",
"      Bay V, Farthmann E, Naegele U. Unoperated funnel chest in middle and advances age: evaluation of indications for operation. J Pediatr Surg 1970; 5:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18071/abstract/19\">",
"      Nuss D, Kelly RE Jr. Minimally invasive surgical correction of chest wall deformities in children (Nuss procedure). Adv Pediatr 2008; 55:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18071/abstract/20\">",
"      Felts E, Jouve JL, Blondel B, et al. Child pectus excavatum: correction by minimally invasive surgery. Orthop Traumatol Surg Res 2009; 95:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18071/abstract/21\">",
"      Colombani PM. Preoperative assessment of chest wall deformities. Semin Thorac Cardiovasc Surg 2009; 21:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18071/abstract/22\">",
"      Saxena AK, Willital GH. Valuable lessons from two decades of pectus repair with the Willital-Hegemann procedure. J Thorac Cardiovasc Surg 2007; 134:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18071/abstract/23\">",
"      Ravitch MM. The Operative Treatment of Pectus Excavatum. Ann Surg 1949; 129:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18071/abstract/24\">",
"      Waters P, Welch K, Micheli LJ, et al. Scoliosis in children with pectus excavatum and pectus carinatum. J Pediatr Orthop 1989; 9:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18071/abstract/25\">",
"      Kelly RE Jr, Shamberger RC, Mellins RB, et al. Prospective multicenter study of surgical correction of pectus excavatum: design, perioperative complications, pain, and baseline pulmonary function facilitated by internet-based data collection. J Am Coll Surg 2007; 205:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18071/abstract/26\">",
"      Calloway EH, Chhotani AN, Lee YZ, Phillips JD. Three-dimensional computed tomography for evaluation and management of children with complex chest wall anomalies: useful information or just pretty pictures? J Pediatr Surg 2011; 46:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18071/abstract/27\">",
"      Haller JA Jr, Kramer SS, Lietman SA. Use of CT scans in selection of patients for pectus excavatum surgery: a preliminary report. J Pediatr Surg 1987; 22:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18071/abstract/28\">",
"      Malek MH, Fonkalsrud EW, Cooper CB. Ventilatory and cardiovascular responses to exercise in patients with pectus excavatum. Chest 2003; 124:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18071/abstract/29\">",
"      Lawson ML, Barnes-Eley M, Burke BL, et al. Reliability of a standardized protocol to calculate cross-sectional chest area and severity indices to evaluate pectus excavatum. J Pediatr Surg 2006; 41:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18071/abstract/30\">",
"      Kim M, Lee KY, Park HJ, et al. Development of new cardiac deformity indexes for pectus excavatum on computed tomography: feasibility for pre- and post-operative evaluation. Yonsei Med J 2009; 50:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18071/abstract/31\">",
"      Kim HC, Park HJ, Ham SY, et al. Development of automatized new indices for radiological assessment of chest-wall deformity and its quantitative evaluation. Med Biol Eng Comput 2008; 46:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18071/abstract/32\">",
"      Marcovici PA, LoSasso BE, Kruk P, Dwek JR. MRI for the evaluation of pectus excavatum. Pediatr Radiol 2011; 41:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18071/abstract/33\">",
"      Lawson ML, Mellins RB, Tabangin M, et al. Impact of pectus excavatum on pulmonary function before and after repair with the Nuss procedure. J Pediatr Surg 2005; 40:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18071/abstract/34\">",
"      POLGAR G, KOOP CE. PULMONARY FUNCTION IN PECTUS EXCAVATUM. Pediatrics 1963; 32:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18071/abstract/35\">",
"      Quigley PM, Haller JA Jr, Jelus KL, et al. Cardiorespiratory function before and after corrective surgery in pectus excavatum. J Pediatr 1996; 128:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18071/abstract/36\">",
"      Fonkalsrud EW. Management of pectus chest deformities in female patients. Am J Surg 2004; 187:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18071/abstract/37\">",
"      Mocchegiani R, Badano L, Lestuzzi C, et al. Relation of right ventricular morphology and function in pectus excavatum to the severity of the chest wall deformity. Am J Cardiol 1995; 76:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18071/abstract/38\">",
"      Kowalewski J, Brocki M, Dryjanski T, et al. Pectus excavatum: increase of right ventricular systolic, diastolic, and stroke volumes after surgical repair. J Thorac Cardiovasc Surg 1999; 118:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18071/abstract/39\">",
"      Krueger T, Chassot PG, Christodoulou M, et al. Cardiac function assessed by transesophageal echocardiography during pectus excavatum repair. Ann Thorac Surg 2010; 89:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18071/abstract/40\">",
"      Sigalet DL, Montgomery M, Harder J. Cardiopulmonary effects of closed repair of pectus excavatum. J Pediatr Surg 2003; 38:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18071/abstract/41\">",
"      Malek MH, Berger DE, Marelich WD, et al. Pulmonary function following surgical repair of pectus excavatum: a meta-analysis. Eur J Cardiothorac Surg 2006; 30:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18071/abstract/42\">",
"      Borowitz D, Cerny F, Zallen G, et al. Pulmonary function and exercise response in patients with pectus excavatum after Nuss repair. J Pediatr Surg 2003; 38:544.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6361 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-F8E45503D2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_41_18071=[""].join("\n");
var outline_f17_41_18071=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cosmetic concerns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - CT scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pulmonary Function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cardiac Function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Exercise Testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6361\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6361|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/8/28800\" title=\"diagnostic image 1\">",
"      Cardiac compression pectus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6361|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/41/8851\" title=\"figure 1\">",
"      Pectus severity index",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6361|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/62/31712\" title=\"picture 1\">",
"      Pectus excavat photo",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10537?source=related_link\">",
"      Causes of short stature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28026?source=related_link\">",
"      Congenital diaphragmatic hernia in the neonate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24490?source=related_link\">",
"      Diseases of the chest wall",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=related_link\">",
"      Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25207?source=related_link\">",
"      Pectus carinatum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21704?source=related_link\">",
"      Pectus excavatum: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/9/8344?source=related_link\">",
"      Spinal muscular atrophy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_41_18072="Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity";
var content_f17_41_18072=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/41/18072/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/41/18072/contributors\">",
"     Brian S Decker, MD, PharmD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/41/18072/contributors\">",
"     Bruce A Molitoris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/41/18072/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/41/18072/contributors\">",
"     Paul M Palevsky, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/41/18072/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/41/18072/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/41/18072/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/41/18072/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main concerns with the use of aminoglycoside antibiotics are nephrotoxicity and ototoxicity. This topic will review what is known about the pathogenesis of these complications and how the nephrotoxicity might be prevented. The manifestations of and risk factors for aminoglycoside nephrotoxicity are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20215?source=see_link\">",
"     \"Manifestations of and risk factors for aminoglycoside nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NEPHROTOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute kidney injury due to acute tubular necrosis is a relatively common complication of aminoglycoside therapy, with a rise in the serum creatinine concentration of more than 0.5 to 1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (44 to 88",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    or a 50 percent increase in serum creatinine concentration from baseline occurring in 10 to 20 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Aminoglycosides are freely filtered across the glomerulus; almost all of the drug is then excreted, with 5 to 10 percent of a parenteral dose being taken up and sequestered by the proximal tubule cells where the aminoglycoside can achieve concentrations vastly exceeding the concurrent serum concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The intracellular accumulation of aminoglycosides is confined primarily to the S1 and S2 segments of the proximal tubule. However, following renal ischemia, the S3 portion is also a site of intracellular aminoglycoside concentrations. Acute kidney injury can occur even if drug levels are closely monitored [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dose frequency also may be important, as multiple human studies suggest that giving a large dose of aminoglycoside once a day is as effective an antimicrobial regimen and less nephrotoxic than giving aminoglycosides in the conventional, divided dose regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/30/8679?source=see_link\">",
"     \"Consolidated aminoglycoside dosing with gentamicin and tobramycin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Renal transport of aminoglycosides",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Proximal tubule cell transport and charge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple amine groups on the aminoglycoside molecule confer a cationic charge at physiologic pH [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. As a result, aminoglycoside molecules readily bind to anion phospholipids within the plasma membrane of the proximal tubule cell (PTC) in a saturable, electrostatic manner [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. The relative affinity of an aminoglycoside for the PTC plasma membrane correlates with the nephrotoxicity observed in clinical practice [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/4,14-16\">",
"     4,14-16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/57/14229?source=see_link\">",
"       Neomycin",
"      </a>",
"      , which has the highest affinity for the PTC binding site, has the greatest nephrotoxicity of the aminoglycosides.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"       Tobramycin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      have lower binding affinity, conferring less nephrotoxicity.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"       Amikacin",
"      </a>",
"      has even less binding affinity and, likewise, has less nephrotoxic potential than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"       tobramycin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"       Streptomycin",
"      </a>",
"      , which has the least affinity for the PTC binding site, has the least nephrotoxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/4,14,15\">",
"       4,14,15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After the aminoglycoside binds to the anionic phospholipid of the PTC, it is rapidly transferred to the transmembrane protein megalin and endocytosed [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/10,11,17-32\">",
"     10,11,17-32",
"    </a>",
"    ]. Megalin is a 600 kD cell surface receptor and has a high affinity for proteins with regions of positively charged amino acids. It is abundantly expressed in the renal proximal tubules and many other tissues, including glomerular podocytes and ciliary and inner ear epithelium [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/10,23,33\">",
"     10,23,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once megalin-mediated endocytosis has occurred, endosomes containing the aminoglycosides are transported through the endocytic system where they co-localize to lysosomes and, in a retrograde fashion, to the Golgi complex [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/30,34-37\">",
"     30,34-37",
"    </a>",
"    ]. From the Golgi complex, aminoglycosides traffic in a retrograde fashion to the endoplasmic reticulum and then to the cytosol [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. In the cytosol, aminoglycoside molecules accumulate in subcellular organelles such as the mitochondria and the nucleus [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This pathway of the aminoglycosides to the Golgi complex and subcellular organelles is consistent with the disruption in both protein sorting and synthesis and mitochondrial function observed in aminoglycoside nephrotoxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Clinical strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical strategies that may minimize the potential for nephrotoxicity include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Selection of the least toxic aminoglycoside when possible.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"       Gentamicin",
"      </a>",
"      is considered the most nephrotoxic followed in decreasing order of nephrotoxicity by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"       tobramycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"       amikacin",
"      </a>",
"      , netilmicin, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"       streptomycin",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Correcting hypokalemia and hypomagnesemia prior to administering an aminoglycoside.",
"     </li>",
"     <li>",
"      Other effective clinical strategies include avoiding aminoglycosides in patients with reduced effective arterial volume, adjusting the dose for renal function, limiting the duration of therapy to 7 to 10 days, and minimizing concomitant nephrotoxic medications [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pharmacokinetically monitoring aminoglycoside therapy and utilizing a once daily dosing regimen in selected patients have also demonstrated benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/5-7,42-45\">",
"       5-7,42-45",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/30/8679?source=see_link\">",
"       \"Consolidated aminoglycoside dosing with gentamicin and tobramycin\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several agents have emerged as potential compounds to prevent aminoglycoside nephrotoxicity. Despite their potential, none have been adopted clinically for the prevention of aminoglycoside nephrotoxicity.",
"   </p>",
"   <p>",
"    One class of compounds, the anionic polyamino acids (PAA), which include polyaspartic acid and polyglutamic acid, has been extensively evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/11,41,46-52\">",
"     11,41,46-52",
"    </a>",
"    ]. Early studies showed that PAA interferes with the binding of the aminoglycoside to PTC plasma membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. Subsequent work showed that PAA binds directly to aminoglycosides and can displace them from negatively charged lysosomes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/53\">",
"     53",
"    </a>",
"    ]. This led researchers to postulate that PAA affords renal protection by directly binding to the aminoglycoside or by displacing it from the lysosome and thus preventing its trafficking through the PTC [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other compounds evaluated for their potential role in preventing aminoglycoside nephrotoxicity include antioxidants. As examples, desferrioxamine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"     methimazole",
"    </a>",
"    , vitamin E, vitamin C, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    have been effective in preventing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    nephrotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/41,54,55\">",
"     41,54,55",
"    </a>",
"    ]. Superoxide dismutase, lipoic acid, dimethyl-sulfoxide (DMSO), N-acetylcysteine, and melatonin have also demonstrated utility in preventing aminoglycoside nephrotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/54,56-61\">",
"     54,56-61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    congener that retains its antimicrobial efficacy and yet lacks the potential for aminoglycoside nephrotoxicity has been isolated. Commercially available gentamicin is not a homogeneous compound; rather, it is a mixture of C1, C1a, C2, and C2a congeners that differ in their nephrotoxic potential [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/62\">",
"     62",
"    </a>",
"    ]. The C2 compound was the specific congener shown to be bactericidal, but not nephrotoxic [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/62\">",
"     62",
"    </a>",
"    ]. Via immunofluorescent techniques, the C2 congener is transported intracellularly to the Golgi complex in reduced quantities. This is likely the reason for its lack of nephrotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Independent of their antimicrobial activity, aminoglycosides are characterized by their ability to induce read-through of premature termination codons, making them potential therapies in the treatment of inherited diseases such as cystic fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/63-66\">",
"     63-66",
"    </a>",
"    ]. Research to develop designer aminoglycosides for this purpose has led to the discovery of aminoglycoside derivatives with less cellular toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/63-66\">",
"     63-66",
"    </a>",
"    ]. However, such compounds also have decreased bactericidal activity and thus would not be effective antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/63,66\">",
"     63,66",
"    </a>",
"    ]. Ongoing research in this area may lead to the discovery of other aminoglycoside derivatives that maintain antibacterial efficacy while minimizing cellular toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     OTOTOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aminoglycosides are associated with cochlear and vestibular toxicity in a substantial proportion of patients receiving the drug for prolonged periods, leading to hearing loss and disequilibrium, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/67\">",
"     67",
"    </a>",
"    ]. The relative frequency with which these occur is uncertain, and both may not be clinically evident in the same patient. In one series of 33 patients presenting to a neurology clinic with vestibular symptoms, formal audiology testing revealed that 10 of 27 tested patients did not have associated hearing loss greater than expected for age [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/68\">",
"     68",
"    </a>",
"    ]. In a later report on 25 patients, most were found to have no residual hearing loss [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical findings and diagnosis of individuals with aminoglycoside vestibulotoxicity is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/38/17001?source=see_link&amp;anchor=H16#H16\">",
"     \"Pathophysiology, etiology, and differential diagnosis of vertigo\", section on 'Aminoglycoside toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of aminoglycoside-induced ototoxicity with hearing loss is less understood. Sustained or excessive peak serum concentrations are thought to be a risk factor.",
"   </p>",
"   <p>",
"    One hypothesis is related to receptors for NMDA (N-methyl-D-aspartate), which are present at the synapse between cochlear hair cells and neural afferents [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/69\">",
"     69",
"    </a>",
"    ]. Aminoglycosides can mimic the positive modulation of polyamines at these receptors, possibly producing excitotoxic damage. The observation that the administration of NMDA antagonists markedly attenuates hearing loss in animals is consistent with this hypothesis. Furthermore, there is a high correlation between in vitro activation of the receptor and relative cochlear toxicity in humans (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    &gt;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    &gt;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    &gt;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/57/14229?source=see_link\">",
"     neomycin",
"    </a>",
"    ). In addition to these functional changes, aminoglycosides also may induce structural changes, such as loss of target innervation and degeneration of spiral ganglion neurons [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another possibility is that aminoglycosides create reactive oxygen species that damage the inner ear. Support for this hypothesis includes the findings of aminoglycoside-induced reactive oxygen species in vitro and experimental evidence in animals showing ototoxicity prevention with antioxidant agents [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/71,72\">",
"     71,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There appears to be a genetic predisposition to the development of ototoxicity with aminoglycosides. Point mutations in the small (12S) ribosomal RNA gene have been described in a number of families with inherited susceptibility to ototoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. The mutant human RNA binds aminoglycosides with high affinity; in comparison, the wild-type human RNA does not bind aminoglycosides at all [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/75\">",
"     75",
"    </a>",
"    ]. The presumed mechanism is that aminoglycoside binding exacerbates the inherent defect induced by the mutation, resulting in a reduction in the overall translation rate below the minimum level required for normal cellular function [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/76\">",
"     76",
"    </a>",
"    ]. The prevalence of such point mutations among individuals of European ancestry is approximately 1 in 500 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/77,78\">",
"     77,78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Prevention of ototoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditionally, a number of the strategies used to help prevent the development of ototoxicity due to aminoglycosides are the same as those used to prevent nephrotoxicity. These strategies include once-daily dosing and careful monitoring of serum drug concentrations. However, ototoxicity has been reported even in those with target serum levels and once-daily dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/5,68\">",
"     5,68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/30/8679?source=see_link\">",
"     \"Consolidated aminoglycoside dosing with gentamicin and tobramycin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another approach is to use audiometric testing among patients receiving aminoglycoside therapy. However, hearing loss may occur even after the termination of antibiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/68,79\">",
"     68,79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic screening of patients prior to administering of aminoglycosides would be a valuable tool to aid in the prevention of ototoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. However, there are no rapid screening tests commercially available that provide results in a clinically relevant time-frame. The patient and family history remain our most valuable tools available to prevent aminoglycoside-induced ototoxicity.",
"   </p>",
"   <p>",
"    In addition, given the relative rarity of the 12S ribosomal point-mutations that confer susceptibility to aminoglycoside-induced hearing loss, it is unlikely that it would be economically feasible to perform general screening or for most laboratories to carry these diagnostic tests. Although aminoglycosides remain powerful tools in our antibiotic armamentarium, there are reasonable alternatives that provide similar spectrums of bacterial coverage. For patients that require gram negative bacterial coverage and whose personal or family history suggests a risk for ototoxicity, considering these antibiotic alternatives may be a more prudent approach.",
"   </p>",
"   <p>",
"    Based upon the observations that oxidative stress may cause ototoxicity, the efficacy of N-acetylcysteine (NAC), a thiol-containing antioxidant, was evaluated in hemodialysis patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/80\">",
"     80",
"    </a>",
"    ]. In this study, 53 hemodialysis patients with catheter-induced bacteremia were randomly assigned to gentamicin plus NAC (600 mg twice daily) or gentamicin alone. Pure-tone audiograms were performed at baseline, one week, and at six weeks after gentamicin therapy was stopped. NAC was given until the first otologic examination, which was approximately one week after completion of antibiotic therapy. Compared with the control group, NAC therapy significantly lowered the incidence of audiologic toxicity (25 versus 60 percent). Protection primarily occurred in the high frequency range, and NAC was not associated with any adverse effects.",
"   </p>",
"   <p>",
"    Another study that included 60 patients on continuous ambulatory peritoneal dialysis (CAPD) suggested that oral administration of NAC prevented ototoxicity related to intraperitoneal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    , and may have improved high-frequency function at four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further study in a larger number of patients and other clinical settings is required to better understand the role of NAC in preventing ototoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/82\">",
"     82",
"    </a>",
"    ]. However, given the proven safety of NAC and the severity and irreversibility of aminoglycoside-induced ototoxicity, a reasonable argument can be made that NAC should be administered to all ESRD patients receiving an aminoglycoside. Such therapy can be particularly considered in hemodialysis patients with existing hearing loss due to previous exposure to aminoglycosides.",
"   </p>",
"   <p>",
"    Limited evidence in non-dialysis patients suggests that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    may provide some protection against ototoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18072/abstract/83-85\">",
"     83-85",
"    </a>",
"    ]. Whether this finding extends to dialysis patients without causing significant adverse effects is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute kidney injury due to acute tubular necrosis is a relatively common complication of aminoglycoside therapy, affecting 10 to 20 percent of patients. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Nephrotoxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Since aminoglycoside molecules readily bind to anionic phospholipids within the plasma membrane of the proximal tubule cell (PTC) in a saturable, electrostatic manner, the relative affinity of an aminoglycoside for the PTC plasma membrane correlates with the nephrotoxicity observed in clinical practice. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Proximal tubule cell transport and charge'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For prevention, clinical strategies are primarily utilized to minimize the potential for nephrotoxicity. These include selection of the least toxic aminoglycoside when possible, correcting hypokalemia and hypomagnesemia prior to administering an aminoglycoside, avoiding aminoglycosides in patients with reduced effective arterial volume, adjusting the dose for renal function, limiting the duration of therapy to 7 to 10 days, and minimizing concomitant nephrotoxic medications. We suggest utilizing a once-daily dosing regimen in selected patients. (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical strategies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although several agents have emerged as potential compounds to prevent aminoglycoside nephrotoxicity, none have been adopted clinically for the prevention of aminoglycoside nephrotoxicity. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aminoglycosides are associated with cochlear and vestibular toxicity in a substantial proportion of patients receiving the drug for prolonged periods, leading to hearing loss and disequilibrium, respectively. The pathogenesis of aminoglycoside-induced ototoxicity with hearing loss is less understood. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Ototoxicity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To prevent the development of ototoxicity due to aminoglycosides, strategies include once-daily dosing and careful monitoring of serum drug concentrations. N-acetylcysteine can also be considered among patients with end-stage renal disease receiving an aminoglycoside. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Prevention of ototoxicity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/1\">",
"      Humes HD. Aminoglycoside nephrotoxicity. Kidney Int 1988; 33:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/2\">",
"      Moore RD, Smith CR, Lipsky JJ, et al. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med 1984; 100:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/3\">",
"      Gall&oslash;e AM, Graudal N, Christensen HR, Kampmann JP. Aminoglycosides: single or multiple daily dosing? A meta-analysis on efficacy and safety. Eur J Clin Pharmacol 1995; 48:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/4\">",
"      Smith CR, Lipsky JJ, Laskin OL, et al. Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med 1980; 302:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/5\">",
"      Munckhof WJ, Grayson ML, Turnidge JD. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother 1996; 37:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/6\">",
"      Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med 1996; 124:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/7\">",
"      Ferriols-Lisart R, Al&oacute;s-Almi&ntilde;ana M. Effectiveness and safety of once-daily aminoglycosides: a meta-analysis. Am J Health Syst Pharm 1996; 53:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/8\">",
"      Barza M, Ioannidis JP, Cappelleri JC, Lau J. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 1996; 312:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/9\">",
"      Prins JM, B&uuml;ller HR, Kuijper EJ, et al. Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993; 341:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/10\">",
"      Nagai J, Takano M. Molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity. Drug Metab Pharmacokinet 2004; 19:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/11\">",
"      Sastrasinh, M, Knauss, TC, Weinberg, JM, Humes, HD. Identification of the aminoglycoside binding site in rat renal brush border membranes. J Pharmacol Ext Ther 1982; 22:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/12\">",
"      Giuliano RA, Verpooten GA, Verbist L, et al. In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats. J Pharmacol Exp Ther 1986; 236:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/13\">",
"      Mingeot-Leclercq MP, Tulkens PM. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother 1999; 43:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/14\">",
"      Smith CR, Baughman KL, Edwards CQ, et al. Controlled comparison of amikacin and gentamicin. N Engl J Med 1977; 296:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/15\">",
"      Lerner AM, Reyes MP, Cone LA, et al. Randomised, controlled trial of the comparative efficacy, auditory toxicity, and nephrotoxicity of tobramycin and netilmicin. Lancet 1983; 1:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/16\">",
"      Williams PD, Bennett DB, Gleason CR, Hottendorf GH. Correlation between renal membrane binding and nephrotoxicity of aminoglycosides. Antimicrob Agents Chemother 1987; 31:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/17\">",
"      Moestrup SK, Cui S, Vorum H, et al. Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs. J Clin Invest 1995; 96:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/18\">",
"      Hammond TG, Majewski RR, Kaysen JH, et al. Gentamicin inhibits rat renal cortical homotypic endosomal fusion: role of megalin. Am J Physiol 1997; 272:F117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/19\">",
"      Christensen, EI, Birn, H. Megalin and cubilin: multifunctional endocytic receptors. Nature Reviews: Molecular Biology 2002; 3:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/20\">",
"      Christensen EI, Birn H. Megalin and cubilin: synergistic endocytic receptors in renal proximal tubule. Am J Physiol Renal Physiol 2001; 280:F562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/21\">",
"      Christensen EI, Willnow TE. Essential role of megalin in renal proximal tubule for vitamin homeostasis. J Am Soc Nephrol 1999; 10:2224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/22\">",
"      Kerjaschki D, Farquhar MG. The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border. Proc Natl Acad Sci U S A 1982; 79:5557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/23\">",
"      Lundgren S, Carling T, Hj&auml;lm G, et al. Tissue distribution of human gp330/megalin, a putative Ca(2+)-sensing protein. J Histochem Cytochem 1997; 45:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/24\">",
"      Schmitz C, Hilpert J, Jacobsen C, et al. Megalin deficiency offers protection from renal aminoglycoside accumulation. J Biol Chem 2002; 277:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/25\">",
"      Cui S, Verroust PJ, Moestrup SK, Christensen EI. Megalin/gp330 mediates uptake of albumin in renal proximal tubule. Am J Physiol 1996; 271:F900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/26\">",
"      Nagai J, Tanaka H, Nakanishi N, et al. Role of megalin in renal handling of aminoglycosides. Am J Physiol Renal Physiol 2001; 281:F337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/27\">",
"      Christensen EI, Birn H, Verroust P, Moestrup SK. Membrane receptors for endocytosis in the renal proximal tubule. Int Rev Cytol 1998; 180:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/28\">",
"      Bennett WM. Mechanisms of aminoglycoside nephrotoxicity. Clin Exp Pharmacol Physiol 1989; 16:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/29\">",
"      Olbricht CJ, Fink M, Gutjahr E. Alterations in lysosomal enzymes of the proximal tubule in gentamicin nephrotoxicity. Kidney Int 1991; 39:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/30\">",
"      Ford DM, Dahl RH, Lamp CA, Molitoris BA. Apically and basolaterally internalized aminoglycosides colocalize in LLC-PK1 lysosomes and alter cell function. Am J Physiol 1994; 266:C52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/31\">",
"      Takano, M, Ohishi, Y, Okuda, M, et al. Transport of gentamicin and fluid-phase endocytosis markers in the LLC-PK1 kidney epithelial cell line. J Pharmacol Exp Therap 1993; 268:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/32\">",
"      Hori R, Okuda M, Ohishi Y, et al. Surface binding and intracellular uptake of gentamicin in the cultured kidney epithelial cell line (LLC-PK1). J Pharmacol Exp Ther 1992; 261:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/33\">",
"      Spiegel DM, Shanley PF, Molitoris BA. Mild ischemia predisposes the S3 segment to gentamicin toxicity. Kidney Int 1990; 38:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/34\">",
"      Wedeen RP, Batuman V, Cheeks C, et al. Transport of gentamicin in rat proximal tubule. Lab Invest 1983; 48:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/35\">",
"      Silverblatt FJ, Kuehn C. Autoradiography of gentamicin uptake by the rat proximal tubule cell. Kidney Int 1979; 15:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/36\">",
"      Servais H, Van Der Smissen P, Thirion G, et al. Gentamicin-induced apoptosis in LLC-PK1 cells: involvement of lysosomes and mitochondria. Toxicol Appl Pharmacol 2005; 206:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/37\">",
"      Sandoval R, Leiser J, Molitoris BA. Aminoglycoside antibiotics traffic to the Golgi complex in LLC-PK1 cells. J Am Soc Nephrol 1998; 9:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/38\">",
"      Sandvig K, Ryd M, Garred O, et al. Retrograde transport from the Golgi complex to the ER of both Shiga toxin and the nontoxic Shiga B-fragment is regulated by butyric acid and cAMP. J Cell Biol 1994; 126:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/39\">",
"      Lord JM, Roberts LM. Toxin entry: retrograde transport through the secretory pathway. J Cell Biol 1998; 140:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/40\">",
"      Sandoval RM, Molitoris BA. Gentamicin traffics retrograde through the secretory pathway and is released in the cytosol via the endoplasmic reticulum. Am J Physiol Renal Physiol 2004; 286:F617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/41\">",
"      Sandvig K, Garred O, van Helvoort A, et al. Importance of glycolipid synthesis for butyric acid-induced sensitization to shiga toxin and intracellular sorting of toxin in A431 cells. Mol Biol Cell 1996; 7:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/42\">",
"      Guo X, Nzerue C. How to prevent, recognize, and treat drug-induced nephrotoxicity. Cleve Clin J Med 2002; 69:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/43\">",
"      Baciewicz AM, Sokos DR, Cowan RI. Aminoglycoside-associated nephrotoxicity in the elderly. Ann Pharmacother 2003; 37:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/44\">",
"      Bailey TC, Little JR, Littenberg B, et al. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997; 24:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/45\">",
"      Bacopoulou F, Markantonis SL, Pavlou E, Adamidou M. A study of once-daily amikacin with low peak target concentrations in intensive care unit patients: pharmacokinetics and associated outcomes. J Crit Care 2003; 18:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/46\">",
"      Ali BH. Agents ameliorating or augmenting experimental gentamicin nephrotoxicity: some recent research. Food Chem Toxicol 2003; 41:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/47\">",
"      Beauchamp D, Laurent G, Maldague P, et al. Protection against gentamicin-induced early renal alterations (phospholipidosis and increased DNA synthesis) by coadministration of poly-L-aspartic acid. J Pharmacol Exp Ther 1990; 255:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/48\">",
"      Kishore BK, Lambricht P, Laurent G, et al. Mechanism of protection afforded by polyaspartic acid against gentamicin-induced phospholipidosis. II. Comparative in vitro and in vivo studies with poly-L-aspartic, poly-L-glutamic and poly-D-glutamic acids. J Pharmacol Exp Ther 1990; 255:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/49\">",
"      Ramsammy LS, Josepovitz C, Lane BP, Kaloyanides GJ. Polyaspartic acid protects against gentamicin nephrotoxicity in the rat. J Pharmacol Exp Ther 1989; 250:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/50\">",
"      Williams PD, Hottendorf GH, Bennett DB. Inhibition of renal membrane binding and nephrotoxicity of aminoglycosides. J Pharmacol Exp Ther 1986; 237:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/51\">",
"      Kishore BK, Ibrahim S, Lambricht P, et al. Comparative assessment of poly-L-aspartic and poly-L-glutamic acids as protectants against gentamicin-induced renal lysosomal phospholipidosis, phospholipiduria and cell proliferation in rats. J Pharmacol Exp Ther 1992; 262:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/52\">",
"      Josepovitz C, Pastoriza-Munoz E, Timmerman D, et al. Inhibition of gentamicin uptake in rat renal cortex in vivo by aminoglycosides and organic polycations. J Pharmacol Exp Ther 1982; 223:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/53\">",
"      Kishore BK, K&aacute;llay Z, Lambricht P, et al. Mechanism of protection afforded by polyaspartic acid against gentamicin-induced phospholipidosis. I. Polyaspartic acid binds gentamicin and displaces it from negatively charged phospholipid layers in vitro. J Pharmacol Exp Ther 1990; 255:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/54\">",
"      Ali BH. Gentamicin nephrotoxicity in humans and animals: some recent research. Gen Pharmacol 1995; 26:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/55\">",
"      Ben Ismail TH, Ali BH, Bashir AA. Influence of iron, deferoxamine and ascorbic acid on gentamicin-induced nephrotoxicity in rats. Gen Pharmacol 1994; 25:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/56\">",
"      Ali BH, Bashir AK. Effect of superoxide dismutase treatment on gentamicin nephrotoxicity in rats. Gen Pharmacol 1996; 27:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/57\">",
"      Ali BH, Mousa HM. Effect of dimethyl sulfoxide on gentamicin-induced nephrotoxicity in rats. Hum Exp Toxicol 2001; 20:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/58\">",
"      Sandya, P, Mohandass, S, Varalakshmi, P. Role of DL a-lipoic acid in gentamicin induced nephrotoxicity. Mol Cell Biochem 2005; 145:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/59\">",
"      Mazzon E, Britti D, De Sarro A, et al. Effect of N-acetylcysteine on gentamicin-mediated nephropathy in rats. Eur J Pharmacol 2001; 424:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/60\">",
"      Reiter RJ, Tan DX, Sainz RM, et al. Melatonin: reducing the toxicity and increasing the efficacy of drugs. J Pharm Pharmacol 2002; 54:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/61\">",
"      Ozbek E, Turkoz Y, Sahna E, et al. Melatonin administration prevents the nephrotoxicity induced by gentamicin. BJU Int 2000; 85:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/62\">",
"      Sandoval RM, Reilly JP, Running W, et al. A non-nephrotoxic gentamicin congener that retains antimicrobial efficacy. J Am Soc Nephrol 2006; 17:2697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/63\">",
"      Nudelman I, Glikin D, Smolkin B, et al. Repairing faulty genes by aminoglycosides: development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutations. Bioorg Med Chem 2010; 18:3735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/64\">",
"      Wang D, Belakhov V, Kandasamy J, et al. The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse. Mol Genet Metab 2012; 105:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/65\">",
"      Rowe SM, Sloane P, Tang LP, et al. Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54. J Mol Med (Berl) 2011; 89:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/66\">",
"      Nudelman I, Rebibo-Sabbah A, Cherniavsky M, et al. Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations. J Med Chem 2009; 52:2836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/67\">",
"      Dobie RA, Black FO, Pezsnecker SC, Stallings VL. Hearing loss in patients with vestibulotoxic reactions to gentamicin therapy. Arch Otolaryngol Head Neck Surg 2006; 132:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/68\">",
"      Black FO, Pesznecker S, Stallings V. Permanent gentamicin vestibulotoxicity. Otol Neurotol 2004; 25:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/69\">",
"      Basile AS, Huang JM, Xie C, et al. N-methyl-D-aspartate antagonists limit aminoglycoside antibiotic-induced hearing loss. Nat Med 1996; 2:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/70\">",
"      Ernfors P, Duan ML, ElShamy WM, Canlon B. Protection of auditory neurons from aminoglycoside toxicity by neurotrophin-3. Nat Med 1996; 2:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/71\">",
"      Wu WJ, Sha SH, Schacht J. Recent advances in understanding aminoglycoside ototoxicity and its prevention. Audiol Neurootol 2002; 7:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/72\">",
"      Sinswat P, Wu WJ, Sha SH, Schacht J. Protection from ototoxicity of intraperitoneal gentamicin in guinea pig. Kidney Int 2000; 58:2525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/73\">",
"      Prezant TR, Agapian JV, Bohlman MC, et al. Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness. Nat Genet 1993; 4:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/74\">",
"      Casano RA, Johnson DF, Bykhovskaya Y, et al. Inherited susceptibility to aminoglycoside ototoxicity: genetic heterogeneity and clinical implications. Am J Otolaryngol 1999; 20:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/75\">",
"      Hamasaki K, Rando RR. Specific binding of aminoglycosides to a human rRNA construct based on a DNA polymorphism which causes aminoglycoside-induced deafness. Biochemistry 1997; 36:12323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/76\">",
"      Guan MX, Fischel-Ghodsian N, Attardi G. A biochemical basis for the inherited susceptibility to aminoglycoside ototoxicity. Hum Mol Genet 2000; 9:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/77\">",
"      Bitner-Glindzicz M, Pembrey M, Duncan A, et al. Prevalence of mitochondrial 1555A--&gt;G mutation in European children. N Engl J Med 2009; 360:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/78\">",
"      Vandebona H, Mitchell P, Manwaring N, et al. Prevalence of mitochondrial 1555A--&gt;G mutation in adults of European descent. N Engl J Med 2009; 360:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/79\">",
"      Aran JM. Current perspectives on inner ear toxicity. Otolaryngol Head Neck Surg 1995; 112:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/80\">",
"      Feldman L, Efrati S, Eviatar E, et al. Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine. Kidney Int 2007; 72:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/81\">",
"      Tokgoz B, Ucar C, Kocyigit I, et al. Protective effect of N-acetylcysteine from drug-induced ototoxicity in uraemic patients with CAPD peritonitis. Nephrol Dial Transplant 2011; 26:4073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/82\">",
"      Tepel M. N-Acetylcysteine in the prevention of ototoxicity. Kidney Int 2007; 72:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/83\">",
"      Chen Y, Huang WG, Zha DJ, et al. Aspirin attenuates gentamicin ototoxicity: from the laboratory to the clinic. Hear Res 2007; 226:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/84\">",
"      Sha SH, Qiu JH, Schacht J. Aspirin to prevent gentamicin-induced hearing loss. N Engl J Med 2006; 354:1856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18072/abstract/85\">",
"      Rybak LP, Ramkumar V. Ototoxicity. Kidney Int 2007; 72:931.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7242 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-41.78.124.10-D68EE5DB58-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_41_18072=[""].join("\n");
var outline_f17_41_18072=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NEPHROTOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Renal transport of aminoglycosides",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Proximal tubule cell transport and charge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Clinical strategies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      OTOTOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Prevention of ototoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/30/8679?source=related_link\">",
"      Consolidated aminoglycoside dosing with gentamicin and tobramycin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20215?source=related_link\">",
"      Manifestations of and risk factors for aminoglycoside nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/38/17001?source=related_link\">",
"      Pathophysiology, etiology, and differential diagnosis of vertigo",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_41_18073="Primary prevention of melanoma";
var content_f17_41_18073=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Primary prevention of melanoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/41/18073/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/41/18073/contributors\">",
"     Alan C Geller, RN, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/41/18073/contributors\">",
"     Susan Swetter, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/41/18073/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/41/18073/contributors\">",
"     Michael B Atkins, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/41/18073/contributors\">",
"     Hensin Tsao, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/41/18073/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/41/18073/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/41/18073/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melanoma has become a worldwide public health concern [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. At least two-thirds of melanoma in light-skinned populations worldwide may be attributed to ultraviolet (UV) radiation exposure from both natural and artificial sources [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/4\">",
"     4",
"    </a>",
"    ]. Based upon this and other data implicating UV light as a risk factor for melanoma, reducing exposure to UV radiation has been advocated as a method to reduce the incidence of this malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Interventions that may be relevant to the primary prevention of melanoma will be reviewed here. Screening and risk factors for melanoma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/16/16650?source=see_link\">",
"     \"Screening and early detection of melanoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=see_link\">",
"     \"Risk factors for the development of melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ULTRAVIOLET RADIATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a causal relationship between ultraviolet (UV) radiation and melanoma has not been directly demonstrated in humans, there is evidence in support of this relationship:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epidemiologic studies have found that the risk of melanoma is higher among fair-skinned people [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/5\">",
"       5",
"      </a>",
"      ]. In the United States, the incidence of melanoma is at least 20 times greater in whites than blacks, and the highest incidence of melanoma worldwide occurs in Queensland, Australia, a subtropical region with a predominantly Celtic population [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=see_link&amp;anchor=H5#H5\">",
"       \"Risk factors for the development of melanoma\", section on 'Risk factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Among families predisposed to melanoma because of genetic mutations, the incidence of melanoma is 21-fold higher for individuals born after 1959 compared with those born before 1900, presumably due to an interaction between increased sun exposure and the predisposing gene mutation [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6569?source=see_link\">",
"       \"Inherited susceptibility to melanoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the laboratory, melanocytic lesions, including melanoma, can be induced in human skin grafted onto mice after exposure to ultraviolet B (UVB) radiation, with or without an initiating carcinogen [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other data implicate ultraviolet A (UVA) radiation, as well as UVB as contributors to melanoma development. Psoriasis patients treated over long periods with a combination of UVA and oral psoralen (PUVA) had a significant increase in melanoma incidence [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/9,10\">",
"       9,10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=see_link&amp;anchor=H10#H10\">",
"       \"Risk factors for the development of melanoma\", section on 'PUVA therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A meta-analysis of 19 population-based case control studies and one cohort study found a 15 percent increased risk of melanoma in individuals who reported they had ever been exposed to tanning beds compared to subjects who had never used tanning devices, and a 75 percent risk increased for individuals who utilized tanning devices before the age of 35 [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/11\">",
"       11",
"      </a>",
"      ]. Multiple other subsequent studies also support an association between tanning bed use and melanoma, particularly for younger cases [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/12-14\">",
"       12-14",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H49280971\">",
"       'Tanning bed use'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=see_link&amp;anchor=H9#H9\">",
"       \"Risk factors for the development of melanoma\", section on 'Tanning beds'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The exact pathways through which ultraviolet radiation can cause melanoma are incompletely understood. Two different epigenetic pathways that can result in cutaneous melanoma are suggested by epidemiologic population-based data [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/15\">",
"     15",
"    </a>",
"    ]. Individuals with an inherently low propensity for melanocyte proliferation may require chronic sun exposure to drive clonal expansion. In contrast, those with a high propensity for melanocyte proliferation (characterized by high nevus count) may require less solar exposure to stimulate carcinogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=see_link&amp;anchor=H12#H12\">",
"     \"Risk factors for the development of melanoma\", section on 'Typical nevi'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unlike keratinocytes, which undergo apoptosis (programmed cell death) when severely damaged by ultraviolet radiation, damaged melanocytes tend to be preserved [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/16\">",
"     16",
"    </a>",
"    ]. This may be related to an effort by the body to continue to produce melanin, which has a photoprotective function in the skin [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/5\">",
"     5",
"    </a>",
"    ]. The result, however, is that severely damaged melanocytes that are at risk for incomplete DNA repair and subsequent mutation are preserved. UVB radiation (290 to 320 nm) causes the majority of DNA damage in the epidermis. However, UVA may also be important in the pathogenesis of melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/17\">",
"     17",
"    </a>",
"    ]. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=see_link&amp;anchor=H6#H6\">",
"     \"Risk factors for the development of melanoma\", section on 'Sun exposure and UV radiation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pattern and timing of exposure to sunlight appear to be important for melanoma development. In contrast to nonmelanoma skin cancers (particularly squamous cell carcinoma), which are associated with cumulative sun exposure and occur most frequently in areas maximally exposed to the sun (ie, the face, back of hands, and forearms), most melanomas are associated with intense intermittent sun exposure and tend to occur in areas exposed to the sun sporadically (eg, the back in men and women and lower legs in women) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Exposure in childhood seems particularly important; a history of five or more severe sunburns in adolescence more than doubles the risk of developing melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/20\">",
"     20",
"    </a>",
"    ]. Furthermore, the incidence of melanoma is increased among people who migrated from northern to more equatorial latitudes, but only among immigrants who were children at the time of migration [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=see_link&amp;anchor=H6#H6\">",
"     \"Risk factors for the development of melanoma\", section on 'Sun exposure and UV radiation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SUN PROTECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classification of ultraviolet radiation as a risk factor for melanoma and other skin cancers is used to support recommendations for sun protection [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/23\">",
"     23",
"    </a>",
"    ]. Sun protection measures should",
"    <sup>",
"    </sup>",
"    include avoidance of midday sun, wearing protective clothing, seeking shade and",
"    <sup>",
"    </sup>",
"    proper use of sunscreens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49281224\">",
"    <span class=\"h2\">",
"     Sunscreen",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18054875\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review for the US Preventive Services Task Force (USPSTF) in 2011 noted only limited high quality evidence that directly links increased sun protective behaviors with a reduction in melanoma incidence [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/24\">",
"     24",
"    </a>",
"    ]. Data from a follow-up study of a community-based, randomized trial in Queensland, Australia, published after the systematic review, support the use of sunscreen products, however [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the Australian trial, 1621 participants were randomly assigned to an intervention group (unlimited supply of SPF 16 sunscreen provided and participants instructed to engage in daily sunscreen use) or a discretionary sunscreen group (participants used their own sunscreen at their own discretion) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/25\">",
"     25",
"    </a>",
"    ]. Ten years after the conclusion of the four-year trial, participants in the intervention group had developed 50 percent fewer primary melanomas compared to the control group (11 versus 22 melanomas; hazard ratio (HR) 0.50; 95% CI 0.24-1.02). The reduction was even greater for invasive melanomas: 3 melanomas occurred in the intervention group versus 11 in the control group (HR 0.27; 95% CI 0.08-0.97), corresponding to a risk reduction of 73 percent. This study provides strong evidence that the regular use of sunscreen reduces the incidence of melanoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2345165\">",
"    <span class=\"h3\">",
"     Labeling and use",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sun protection factor (SPF) used to assess the efficacy of sunscreens primarily measures the protection against UVB [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/26\">",
"     26",
"    </a>",
"    ]. SPF refers to the ratio of the minimal dose of solar radiation that produces perceptible erythema (minimal erythema dose, MED) on the skin protected by sunscreen and the MED for unprotected skin. The SPF is assessed in experimental conditions using a light source that simulates the solar radiation on the skin of volunteers who have applied a sunscreen at a concentration of 2",
"    <span class=\"nowrap\">",
"     mg/cm",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/27\">",
"     27",
"    </a>",
"    ]. In the experimental setting, the benefits of sunscreen with an SPF factor higher than 15 are minimal in terms of additional UVB protection [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The SPF does not adequately measure the protection from UVA, which comprises 95 percent of the total UV radiation that reaches the earth at sea level. The lack of adequate information on the degree of UVA protection provided by sunscreens prompted the US Food and Drug Administration (FDA) to issue new regulations for labeling sunscreen products in 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/29\">",
"     29",
"    </a>",
"    ]. Under the new regulations only sunscreen products that pass the FDA&rsquo;s test for protection against both ultraviolet A (UVA) and ultraviolet B (UVB) rays will be labeled as &ldquo;broad spectrum.&rdquo; The UVA protection will not be rated. Sunscreen products that meet the FDA&rsquo;s standards and contain a sun protection factor (SPF) of 15 or higher can be designated as sunscreens that, if used as directed with other sun protection measures, decrease the risk of skin cancer and early skin aging caused by the sun. The new regulation will be effective June 2012.",
"   </p>",
"   <p>",
"    A 5-star rating system for UVA protection has been recommended to the industry by the European Union, where a number of UVA sunscreen agents, including bemotrizinol and drometrizole trisiloxane, have been available for many years. The UVA protection level refers to the ratio of",
"    <span class=\"nowrap\">",
"     UVB/UVA",
"    </span>",
"    protection, and is required to be at least one third of the labeled SPF. Several new broad spectrum sunscreens are available in the United States that include ecamsule and avobenzone (photo-stabilized with octocrylene) (",
"    <a class=\"graphic graphic_table graphicRef58215 \" href=\"UTD.htm?8/51/9019\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/30\">",
"     30",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    For sunscreen to work effectively, it must be applied liberally, repeatedly, and to all sun-exposed parts of the skin to prevent sunburn. Most people do not apply enough sunscreen (2",
"    <span class=\"nowrap\">",
"     mg/cm",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    to achieve the claimed SPF [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/31\">",
"     31",
"    </a>",
"    ]. For an average-sized adult, the amount of sunscreen necessary to cover exposed skin is roughly the equivalent of the amount required to fill a 1 ounce shot glass. Typically, only enough sunscreen is applied to achieve one-third to one-half of its rated SPF value [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/32\">",
"     32",
"    </a>",
"    ]. Thus, the",
"    <a class=\"external\" href=\"file://www.aad.org/media-resources/stats-and-facts/prevention-and-care/sunscreens\">",
"     American Academy of Dermatology",
"    </a>",
"    recommends the use of a sunscreen with an",
"    <strong>",
"     SPF of at least 30",
"    </strong>",
"    during sun exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/33\">",
"     33",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Clinicians must also alert patients not to use sunscreen as a means of spending longer amounts of time in the sun. Sunscreen use may lead to longer time spent in the sun since sunscreens delay sunburn occurrence. This was illustrated in a study that randomly assigned 87 individuals, aged 18 to 24 years, to use a sunscreen containing SPF 10 or 30 prior to the summer holiday [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/34\">",
"     34",
"    </a>",
"    ]. The mean cumulative sun exposure was 58 and 73 hours, respectively. However, a later study with more subjects found that higher SPF had no influence on duration of sun exposure and offered better sun protection against sunburns [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H933448\">",
"    <span class=\"h2\">",
"     Other measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to use of sunscreen products, other approaches also may be useful to decrease exposure to UV light. Developments in the glass industry have resulted in window glass and sunglasses that provide UV protection without the historically associated loss of visible light transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Wearing clothes is important for sun protection. The degree of protection provided by clothes is defined by the ultraviolet protection factor (UPF), which indicates how effective a fabric is at blocking out solar ultraviolet radiation. The Australian Radiation Protection and Nuclear Safety Agency introduced a standardized UPF testing method for fabrics in 1996 and established rules for appropriate labeling of clothes claiming to offer sun protection [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors that contribute to the UPF rating of a fabric are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Composition of the yarns (cotton, polyester, etc)",
"     </li>",
"     <li>",
"      Tightness of the weave or knit (tighter improves the rating)",
"     </li>",
"     <li>",
"      Color (darker colors are generally better)",
"     </li>",
"     <li>",
"      Stretch (more stretch lowers the rating)",
"     </li>",
"     <li>",
"      Moisture (many fabrics have lower ratings when wet)",
"     </li>",
"     <li>",
"      Condition (worn and faded garments may have reduced ratings)",
"     </li>",
"     <li>",
"      Finishing (some fabrics are treated with UV absorbing chemicals)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Skin Cancer Foundation in the United States has developed a list of products, including cosmetics, clothes, and laundry additives, that can provide sun protection [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49279486\">",
"    <span class=\"h2\">",
"     Sun protection and nevi",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of atypical nevi or high numbers of common nevi has been associated with increased risk for melanoma. Although sun protective measures in children have been linked with the development of fewer nevi [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/40,41\">",
"     40,41",
"    </a>",
"    ], it remains unclear whether sun protection can reduce the risk for melanoma through this pathway. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=see_link&amp;anchor=H12#H12\">",
"     \"Risk factors for the development of melanoma\", section on 'Typical nevi'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=see_link&amp;anchor=H18#H18\">",
"     \"Risk factors for the development of melanoma\", section on 'Atypical nevi'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following studies support the effect of sun protection on reductions in nevi count:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sunscreen use has been shown to modestly attenuate the development of new moles in young children. In a randomized trial, Caucasian schoolchildren were randomly assigned to receive either SPF 30 broad-spectrum sunscreen (with instructions to apply it if sun exposure was expected to last 30 minutes or longer) or to no intervention [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/41\">",
"       41",
"      </a>",
"      ]. Children in the sunscreen group developed fewer nevi over a three-year period (median count 24 versus 28, without sunscreen). The use of sunscreen was especially beneficial for freckled children in the intervention group. These children developed 30 to 40 percent fewer nevi than those in the control group.",
"     </li>",
"     <li>",
"      At least two studies suggest that the use of a physical barrier (clothing) to prevent sun exposure may be of value for reducing the number of nevi. In one report of 12 year old children who had been followed for more than six years, those who covered their backs all of the time had fewer new nevi than children who covered their backs less than 70 percent of the time [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study found that children who wore more clothing during holidays in sunny climates developed fewer nevi [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/43\">",
"       43",
"      </a>",
"      ]. Multivariate analysis in this study did not demonstrate a benefit from the use of sunscreen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional studies are necessary to determine the relationship between sun protection, nevi count, and risk of melanoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18054779\">",
"    <span class=\"h2\">",
"     General guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several guidelines have been developed by scientific and specialty groups for protection from exposure to the sun [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/44-50\">",
"     44-50",
"    </a>",
"    ]. The National Council on Skin Cancer Prevention, which is comprised of more than 40 skin cancer organizations and foundations in the United States, adopted the following recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/46\">",
"     46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Do not burn; avoid sun tanning and tanning beds. Ultraviolet light from the sun and tanning beds causes skin cancer and wrinkling. Consider using a sunless self-tanning product to simulate the appearance of having been in the sun, but continue to use sunscreen.",
"     </li>",
"     <li>",
"      Generously apply sunscreen to all exposed skin using a Sun Protection Factor (SPF) of at least 15 which provides broad-spectrum protection from both ultraviolet A (UVA) and ultraviolet B (UVB) radiation. Re-apply every two hours, even on cloudy days, and after swimming or sweating.",
"     </li>",
"     <li>",
"      Wear protective clothing such as a long-sleeved shirt, pants, a wide-brimmed hat and sunglasses, where possible.",
"     </li>",
"     <li>",
"      Seek shade when appropriate, remembering that the sun's rays are the strongest between 10 AM and 4 PM.",
"     </li>",
"     <li>",
"      Use extra caution near water, snow and sand as they reflect the damaging rays of the sun which can increase the chance of sunburn.",
"     </li>",
"     <li>",
"      Get vitamin D safely through a healthy diet that includes vitamin supplements.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Status of sun protection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Participation in sun protective measures has varied over time and with population demographics. Examples of data on the use of sun protection include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 1998 and 2004, cross-sectional surveys of youth aged 11 to 18 years in the United States were conducted (n = 1196 and n=1613, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/51\">",
"       51",
"      </a>",
"      ]. In 2004, 69 percent of subjects reported having been sunburned during the summer, not significantly less than in 1998 (72 percent). However, the youngest children reported a significant decrease in sunburns. Sunscreen use, the most common form of sun protection, increased significantly while other sun protection measures did not change.",
"     </li>",
"     <li>",
"      More than 28,000 adults participated in the 2005 National Health Interview Survey (NHIS) and were asked questions regarding sun-protection behaviors and sunburns in the past year. Sun protection practices were weakest among youngest adults, persons residing in the Midwest, males, non-Hispanic whites, those who were less-educated, smokers, risky drinkers, and individuals that had skin that was less sun-sensitive [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a series of more than 10,000 children of nurses from the Nurses Health Study, only 34 percent of children aged 11 to 18 were using sunscreen, and 83 percent had at least one sunburn during the previous summer [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Observational studies have noted deficits in shade-seeking and covering up among all age groups [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/54\">",
"     54",
"    </a>",
"    ]. Protective practices appear to be more prevalent at the beach or on vacation than in other outdoor recreation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/55\">",
"     55",
"    </a>",
"    ]. Parents are more likely to protect their children than themselves, although they often do not provide adequate protection for their children. One randomized trial that investigated the impact of parent education on sun protection for children found that taken together, 22 and 54 percent of children in the intervention and control groups received a sunburn or tan during their first and second summers of life, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/56\">",
"     56",
"    </a>",
"    ]. Likewise, a study of Swedish toddlers found that 20 percent had been severely sunburned at least once before their first birthday [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/57\">",
"     57",
"    </a>",
"    ]. Persons with fairer skin, higher education, more knowledge, and greater fear of skin cancer, females, and those who know someone with skin cancer generally practice more preventive habits.",
"   </p>",
"   <p>",
"    Perceived social norms appear especially important among adolescents and young adults. Positive attitudes toward tanning (ie, healthy, attractive) predict a lower use of sun protection [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/58\">",
"     58",
"    </a>",
"    ]. Young teens&rsquo; practice of sun protection tends to modestly decrease as peer pressure and fashion concerns start to influence their behavior. In a prospective study involving 360 fifth-grade children, 50 percent of students reported \"often or always\" use of sunscreen when outside for at least six hours in the summer [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/59\">",
"     59",
"    </a>",
"    ]. At the follow-up evaluation three years later, this proportion dropped to 25 percent. At the same time, more children reported &ldquo;liking a tan&rdquo; and spending time in the sun to get a tan.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H933833\">",
"    <span class=\"h2\">",
"     Vitamin D deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strict sun protection can increase the risk for vitamin D deficiency. Oral vitamin D supplementation is a safe, well-tolerated, and inexpensive alternative to achieve adequate vitamin D levels [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=see_link\">",
"     \"Treatment of vitamin D deficiency in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/38/28266?source=see_link\">",
"     \"Vitamin D insufficiency and deficiency in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49280971\">",
"    <span class=\"h1\">",
"     TANNING BED USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The working group of the International Agency for Research on Cancer concluded that tanning bed use in youth was associated with skin cancer and documented a 75 percent increase in melanoma for those who first used tanning beds in their twenties or teen years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/11\">",
"     11",
"    </a>",
"    ]. Based upon these findings, the working group concluded that minors and young adults should avoid the use of tanning devices and supported restricting access to artificial tanning facilities for individuals under the age of 18 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/62\">",
"     62",
"    </a>",
"    ]. The American Academy of Pediatrics recommends that pediatricians advocate for legislation to ban access to tanning parlors for children younger than 18 years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/50\">",
"     50",
"    </a>",
"    ]. Increased risk for melanoma has also been detected in patients who begin tanning in mid-adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=see_link&amp;anchor=H9#H9\">",
"     \"Risk factors for the development of melanoma\", section on 'Tanning beds'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon evidence implicating tanning bed use as a risk factor for melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/11-14\">",
"     11-14",
"    </a>",
"    ], the recreational use of tanning devices should be avoided. However, tanning bed users have reported relaxation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/63\">",
"     63",
"    </a>",
"    ], pain relief [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/64,65\">",
"     64,65",
"    </a>",
"    ], and improved mood [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/66\">",
"     66",
"    </a>",
"    ] as motivation for continuing this practice, and there is increasing evidence that biochemical addiction to tanning can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/67-69\">",
"     67-69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism for an addiction to tanning is unconfirmed. It has been proposed that UV-induced production of pro-opiomelanocortin products including beta endorphins may be a contributing factor. This theory was supported by the findings of a small randomized trial in which opioid blockade with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    was associated with a reduced preference of UV exposure among frequent tanners [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/70\">",
"     70",
"    </a>",
"    ]. Administration of naltrexone also led to withdrawal symptoms in four out of eight frequent tanners, while no infrequent tanners experienced withdrawal-like symptoms. However, the relationship between tanning bed exposure and opioid production remains controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If a true entity, addiction to tanning may be common. In one study of college students, 90 out of 229 students who reported tanning bed use (39 percent) met the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV-TR criteria for addiction [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/72\">",
"     72",
"    </a>",
"    ]. Tanning bed addiction may be more common in individuals with anxiety, depressive symptoms, or substance abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/69,72\">",
"     69,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further studies are necessary to determine the relationship between tanning and psychiatric disorders and the best approach to patients who exhibit signs of a tanning addiction. In the interim, clinicians should remain cognizant that psychological factors may play a role in the reluctance or inability of some patients to stop tanning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49280705\">",
"    <span class=\"h1\">",
"     CHEMOPREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemoprevention, defined as the use of natural or synthetic agents to delay, reverse, suppress, or prevent premalignant lesions from progressing to invasive cancer, has been evaluated in melanoma and other skin cancers as a means of primary prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/73-75\">",
"     73-75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H932772\">",
"    <span class=\"h2\">",
"     Vitamin D",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sun exposure is necessary for the synthesis of 25-hydroxyvitamin D in the skin. This intermediate metabolite is transformed to its biologically active form under conditions of physiological demand for calcium and phosphorus. The potential health benefits of vitamin D continue to be explored as the incidence and survival of major internal cancers is known to improve significantly with decreasing latitudes in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/76\">",
"     76",
"    </a>",
"    ]. The antiproliferative and proapoptotic effects of active vitamin D (ie, 1,25-dihydroxyvitamin D) may be a factor in the association of vitamin D with lower risk for some malignancies (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/24/42378?source=see_link&amp;anchor=H15#H15\">",
"     \"Cancer prevention\", section on 'Vitamin D'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An effect of vitamin D on melanoma pathogenesis was suggested by a case control study of 500 melanoma patients, in which sun exposure, as measured by solar elastosis, was associated with increased survival [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/77\">",
"     77",
"    </a>",
"    ]. However, serum vitamin D levels were not assessed in this study, and vitamin D levels are unlikely to be the only reason for this observation, particularly given our growing understanding of \"diverging\" melanoma pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=see_link&amp;anchor=H13#H13\">",
"     \"Risk factors for the development of melanoma\", section on 'Quantity of nevi'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H932779\">",
"    <span class=\"h3\">",
"     Dietary vitamin D",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies investigating the impact of dietary vitamin D on the risk of melanoma have shown conflicting results.",
"   </p>",
"   <p>",
"    Although in vitro and in vivo mouse studies have suggested a protective effect of vitamin D on melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/78-83\">",
"     78-83",
"    </a>",
"    ], a prospective cohort study involving 68,611 men and women found no association between vitamin D intake and the occurrence of melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/84\">",
"     84",
"    </a>",
"    ]. An earlier case-control study found no association of melanoma risk with total vitamin D intake [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At least two studies of dietary vitamin D and melanoma risk have resulted in other conclusions. A case-control study of more than 1000 subjects identified a significant reduction of melanoma risk for individuals with high vitamin D intake [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/86\">",
"     86",
"    </a>",
"    ]. Conversely, a large prospective study reported an increased risk of melanoma associated with cod liver oil intake (a source of vitamin D) among women, but not men [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Calcium plus vitamin D supplementation did not reduce the overall incidence of melanoma or nonmelanoma skin cancer (NMSC) in postmenopausal women in the Women's Health Initiative (WHI) (HR 0.86, 95% CI 0.64-1.16) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/88\">",
"     88",
"    </a>",
"    ]. However, in a subgroup analysis of participants who reported a history of NMSC, women in the vitamin D and calcium group had 57 percent fewer melanomas than women in the placebo group (HR 0.43, 95% CI 0.21-0.90). This finding suggests a role for either vitamin D or calcium, or their combination in reducing the incidence of melanoma in a high-risk group of postmenopausal women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28796151\">",
"    <span class=\"h2\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipid-lowering drugs, such as statins and fibrates, have been evaluated. Two systemic reviews and meta-analyses of randomized trials of statins and fibrates for the prevention of heart disease were unable to identify a statistically significant effect of lipid-lowering drugs on melanoma risk [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/75,89\">",
"     75,89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonsteroidal antiinflammatory agents (NSAID) have also been suggested as having chemopreventive effects against melanoma. However, observational studies of different medications and in different populations have provided conflicting evidence, as illustrated below.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A large cohort study did not find any association between NSAID use and melanoma risk [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/90\">",
"       90",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A case-control study found that the continuous use of acetylsalicylic acid (ASA) for more than five years was associated with a 50 percent reduction in melanoma risk in women and men. This study also suggested that long-term use of non-ASA NSAID may also be protective against melanoma development [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/91\">",
"       91",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another case-control study provided evidence of a protective effect of long-term use of low-dose ASA in women [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/92\">",
"       92",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A large population-based case-control study found that individuals using NSAIDs (&gt;2 prescriptions) has a 13 percent reduction in the risk of melanoma than nonusers. The risk reduction was greater (approximately 50 percent) for long-term and high-intensity use [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49281264\">",
"    <span class=\"h1\">",
"     PUBLIC HEALTH MEASURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of public health measures have been implemented in an attempt to reduce the risk of skin cancers, including melanoma. Examples include government-sponsored efforts, such as the",
"    <a class=\"external\" href=\"file://www.sunsmart.com.au/\">",
"     SunSmart&reg;",
"    </a>",
"    campaign in Australia, and the Environmental Protection Agency&rsquo;s",
"    <a class=\"external\" href=\"file://www.epa.gov/sunwise/\">",
"     SunWise",
"    </a>",
"    <sup>",
"     &reg;",
"    </sup>",
"    Program in the United States. The media is another outlet for increasing awareness of sun protection; some television stations and newspapers notify the public of days on which the risk of high UV exposure is elevated. However, no studies have directly linked the implementation of public health programs to a reduction in melanoma incidence.",
"   </p>",
"   <p>",
"    Clinician efforts to educate patients on protection from ultraviolet light exposure may influence patient behavior. A systematic review performed for the US Preventive Services Task Force (USPSTF) found that patient counseling with tailored feedback in the primary care setting was associated with modest improvement in sun protective practices and reduced indoor tanning [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/24\">",
"     24",
"    </a>",
"    ]. The USPSTF recommends counseling children, adolescents, and young adults aged 10 to 24 years who have fair skin about minimizing their exposure to ultraviolet radiation to reduce the risk of skin cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18073/abstract/94\">",
"     94",
"    </a>",
"    ]. The task force further recommended &ldquo;appearance-based counseling&rdquo; to focus on the effect of UV exposure on skin appearance (ie, photoaging), rather than focusing on skin cancer risk alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/20/23874?source=see_link\">",
"       \"Patient information: Sunburn (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/30/18913?source=see_link\">",
"       \"Patient information: Sunburn (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?32/60/33729?source=see_link\">",
"       \"Patient information: Sunburn prevention (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49280784\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ultraviolet (UV) radiation has been implicated as a risk factor for melanoma. Although studies of the impact of UV-protective measures on melanoma incidence are limited, interventions to reduce individual exposure to UV light are recommended. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Ultraviolet radiation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Sun protection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Shade structures, clothing, sunscreen, and other measures can provide sun protection. Consistent daily application of sunscreen with an SPF of 15 or greater is likely sufficient to provide protection. However, sunscreens with an SPF of at least 30 have been recommended in guidelines because of inconsistent use. Sunscreen with an SPF of at least 30 should be applied to all exposed skin during sun exposure. Broad spectrum sunscreens offer both UVB and UVA protection. Sunscreen should be applied liberally, and reapplication should occur every two hours or after swimming or sweating. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Sun protection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Individuals at increased risk of melanoma and individuals highly exposed to sunlight should apply sunscreen daily and thoroughly before going out. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=see_link\">",
"       \"Risk factors for the development of melanoma\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H5\">",
"       'Sun protection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Atypical nevi and high numbers of typical nevi are risk factors for the development of melanoma. Sun protection has been shown to reduce the development of nevi in children. However, it remains unclear whether sun protection can reduce the risk of melanoma through this pathway. (See",
"      <a class=\"local\" href=\"#H49279486\">",
"       'Sun protection and nevi'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tanning bed use is associated with an increased risk for melanoma and should be avoided. Additional studies are necessary to explore whether some individuals develop a biochemical addiction to tanning. (See",
"      <a class=\"local\" href=\"#H49280971\">",
"       'Tanning bed use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is limited and conflicting evidence that vitamin D, non-steroidal antiinflammatory agents, or lipid lowering agents have a chemopreventive effect on melanoma. (See",
"      <a class=\"local\" href=\"#H49280705\">",
"       'Chemoprevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of public health programs, most notably the Australian SunSmart campaign, have resulted in improved sun protection as well as stabilization of incidence rates that were increasing precipitously in earlier years. Further studies are necessary to determine the impact of similar public health programs on the primary prevention of melanoma elsewhere. (See",
"      <a class=\"local\" href=\"#H49281264\">",
"       'Public health measures'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/1\">",
"      Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/2\">",
"      Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999; 80:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/3\">",
"      Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/4\">",
"      Armstrong BK, Kricker A. How much melanoma is caused by sun exposure? Melanoma Res 1993; 3:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/5\">",
"      Gilchrest BA, Eller MS, Geller AC, Yaar M. The pathogenesis of melanoma induced by ultraviolet radiation. N Engl J Med 1999; 340:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/6\">",
"      MacLennan R, Green AC, McLeod GR, Martin NG. Increasing incidence of cutaneous melanoma in Queensland, Australia. J Natl Cancer Inst 1992; 84:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/7\">",
"      Battistutta D, Palmer J, Walters M, et al. Incidence of familial melanoma and MLM2 gene. Lancet 1994; 344:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/8\">",
"      Atillasoy ES, Seykora JT, Soballe PW, et al. UVB induces atypical melanocytic lesions and melanoma in human skin. Am J Pathol 1998; 152:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/9\">",
"      Stern RS, PUVA Follow up Study. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001; 44:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/10\">",
"      Stern RS, Nichols KT, V&auml;kev&auml; LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. N Engl J Med 1997; 336:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/11\">",
"      International Agency for Research on Cancer Working Group on artificial ultraviolet (UV) light and skin cancer. The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: A systematic review. Int J Cancer 2007; 120:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/12\">",
"      Lazovich D, Vogel RI, Berwick M, et al. Indoor tanning and risk of melanoma: a case-control study in a highly exposed population. Cancer Epidemiol Biomarkers Prev 2010; 19:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/13\">",
"      Cust AE, Armstrong BK, Goumas C, et al. Sunbed use during adolescence and early adulthood is associated with increased risk of early-onset melanoma. Int J Cancer 2011; 128:2425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/14\">",
"      H&eacute;ry C, Tryggvad&oacute;ttir L, Sigurdsson T, et al. A melanoma epidemic in Iceland: possible influence of sunbed use. Am J Epidemiol 2010; 172:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/15\">",
"      Whiteman DC, Watt P, Purdie DM, et al. Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst 2003; 95:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/16\">",
"      Young AR. The sunburn cell. Photodermatol 1987; 4:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/17\">",
"      Wang SQ, Setlow R, Berwick M, et al. Ultraviolet A and melanoma: a review. J Am Acad Dermatol 2001; 44:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/18\">",
"      Nelemans PJ, Groenendal H, Kiemeney LA, et al. Effect of intermittent exposure to sunlight on melanoma risk among indoor workers and sun-sensitive individuals. Environ Health Perspect 1993; 101:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/19\">",
"      Elwood JM, Gallagher RP, Hill GB, Pearson JC. Cutaneous melanoma in relation to intermittent and constant sun exposure--the Western Canada Melanoma Study. Int J Cancer 1985; 35:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/20\">",
"      Weinstock MA. Controversies in the role of sunlight in the pathogenesis of cutaneous melanoma. Photochem Photobiol 1996; 63:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/21\">",
"      Cooke KR, Fraser J. Migration and death from malignant melanoma. Int J Cancer 1985; 36:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/22\">",
"      Holman CD, Armstrong BK. Cutaneous malignant melanoma and indicators of total accumulated exposure to the sun: an analysis separating histogenetic types. J Natl Cancer Inst 1984; 73:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/23\">",
"      IARC monographs on the evaluation of carcinogenic risks to humans. Solar and ultraviolet radiation. IARC Monogr Eval Carcinog Risks Hum 1992; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/24\">",
"      Lin JS, Eder M, Weinmann S. Behavioral counseling to prevent skin cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 154:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/25\">",
"      Green AC, Williams GM, Logan V, Strutton GM. Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol 2011; 29:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/26\">",
"      Gasparro FP, Mitchnick M, Nash JF. A review of sunscreen safety and efficacy. Photochem Photobiol 1998; 68:243.",
"     </a>",
"    </li>",
"    <li>",
"     Lim HW, Honigsmann H. Photoprotection. In: Photodermatology, Lim HW, Honigsmann H, Hawk JLM.  (Eds), Informa Healthcare, New York 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/28\">",
"      Sunscreens: are they safe and effective? Med Lett Drugs Ther 1999; 41:43.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.ofr.gov/OFRUpload/OFRData/2011-14766_PI.pdf (Accessed on June 15, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/30\">",
"      Bissonnette R. Update on sunscreens. Skin Therapy Lett 2008; 13:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/31\">",
"      Neale R, Williams G, Green A. Application patterns among participants randomized to daily sunscreen use in a skin cancer prevention trial. Arch Dermatol 2002; 138:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/32\">",
"      Naylor MF, Farmer KC. The case for sunscreens. A review of their use in preventing actinic damage and neoplasia. Arch Dermatol 1997; 133:1146.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.aad.org/public/sun/smart.html.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/34\">",
"      Autier P, Dor&eacute; JF, N&eacute;grier S, et al. Sunscreen use and duration of sun exposure: a double-blind, randomized trial. J Natl Cancer Inst 1999; 91:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/35\">",
"      Dupuy A, Dunant A, Grob JJ, R&eacute;seau d'Epid&eacute;miologie en Dermatologie. Randomized controlled trial testing the impact of high-protection sunscreens on sun-exposure behavior. Arch Dermatol 2005; 141:950.",
"     </a>",
"    </li>",
"    <li>",
"     file://www/fda.gov/consumer/updated/sunscreen082307.html.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/37\">",
"      Tuchinda C, Srivannaboon S, Lim HW. Photoprotection by window glass, automobile glass, and sunglasses. J Am Acad Dermatol 2006; 54:845.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.arpansa.gov.au/services/upf/index.cfm (Accessed on April 04, 2011).",
"    </li>",
"    <li>",
"     file://www.skincancer.org/seal/#sealfinder.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/40\">",
"      Harrison SL, Buettner PG, Maclennan R. The North Queensland \"Sun-Safe Clothing\" study: design and baseline results of a randomized trial to determine the effectiveness of sun-protective clothing in preventing melanocytic nevi. Am J Epidemiol 2005; 161:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/41\">",
"      Gallagher RP, Rivers JK, Lee TK, et al. Broad-spectrum sunscreen use and the development of new nevi in white children: A randomized controlled trial. JAMA 2000; 283:2955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/42\">",
"      English DR, Milne E, Jacoby P, et al. The effect of a school-based sun protection intervention on the development of melanocytic nevi in children: 6-year follow-up. Cancer Epidemiol Biomarkers Prev 2005; 14:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/43\">",
"      Bauer J, B&uuml;ttner P, Wiecker TS, et al. Effect of sunscreen and clothing on the number of melanocytic nevi in 1,812 German children attending day care. Am J Epidemiol 2005; 161:620.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute for Health and Clinicaql Excellence. PH32 Skin cancer prevention: information, resources and environmental changes: guidance file://guidance.nice.org.uk/PH32/Guidance/pdf/English (Accessed on April 04, 2011).",
"    </li>",
"    <li>",
"     file://www.cancer.org.au/cancersmartlifestyle/SunSmart/Preventingskincancer.htm (Accessed on April 04, 2011).",
"    </li>",
"    <li>",
"     National Council on Skin Cancer Prevention www.skincancerprevention.org (Accessed on January 25, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/47\">",
"      Harmful effects of ultraviolet radiation. Council on Scientific Affairs. JAMA 1989; 262:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/48\">",
"      Goldsmith L, Koh HK, Bewerse B, et al. Proceedings from the national conference to develop a national skin cancer agenda. American Academy of Dermatology and Centers for Disease Control and Prevention, April 8-10, 1995. J Am Acad Dermatol 1996; 34:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/49\">",
"      Balk SJ, Council on Environmental Health, Section on Dermatology. Ultraviolet radiation: a hazard to children and adolescents. Pediatrics 2011; 127:e791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/50\">",
"      Council on Environmental Health, Balk SJ. Ultraviolet radiation: a hazard to children and adolescents. Pediatrics 2011; 127:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/51\">",
"      Cokkinides V, Weinstock M, Glanz K, et al. Trends in sunburns, sun protection practices, and attitudes toward sun exposure protection and tanning among US adolescents, 1998-2004. Pediatrics 2006; 118:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/52\">",
"      Coups EJ, Manne SL, Heckman CJ. Multiple skin cancer risk behaviors in the U.S. population. Am J Prev Med 2008; 34:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/53\">",
"      Geller AC, Colditz G, Oliveria S, et al. Use of sunscreen, sunburning rates, and tanning bed use among more than 10 000 US children and adolescents. Pediatrics 2002; 109:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/54\">",
"      Koh HK, Geller AC. Public health interventions for melanoma. Prevention, early detection, and education. Hematol Oncol Clin North Am 1998; 12:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/55\">",
"      Miller DR, Geller AC, Wood MC, et al. The Falmouth Safe Skin Project: evaluation of a community program to promote sun protection in youth. Health Educ Behav 1999; 26:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/56\">",
"      Benjes LS, Brooks DR, Zhang Z, et al. Changing patterns of sun protection between the first and second summers for very young children. Arch Dermatol 2004; 140:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/57\">",
"      Br&auml;nstr&ouml;m R, Kristjansson S, Dal H, Rodvall Y. Sun exposure and sunburn among Swedish toddlers. Eur J Cancer 2006; 42:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/58\">",
"      McGee R, Williams S. Adolescence and sun protection. N Z Med J 1992; 105:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/59\">",
"      Dusza SW, Halpern AC, Satagopan JM, et al. Prospective study of sunburn and sun behavior patterns during adolescence. Pediatrics 2012; 129:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/60\">",
"      Egan KM, Sosman JA, Blot WJ. Sunlight and reduced risk of cancer: is the real story vitamin D? J Natl Cancer Inst 2005; 97:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/61\">",
"      Lim HW, Gilchrest BA, Cooper KD, et al. Sunlight, tanning booths, and vitamin D. J Am Acad Dermatol 2005; 52:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/62\">",
"      Autier P, Boyle P. Artificial ultraviolet sources and skin cancers: rationale for restricting access to sunbed use before 18 years of age. Nat Clin Pract Oncol 2008; 5:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/63\">",
"      Feldman SR, Liguori A, Kucenic M, et al. Ultraviolet exposure is a reinforcing stimulus in frequent indoor tanners. J Am Acad Dermatol 2004; 51:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/64\">",
"      Kaur M, Feldman SR, Liguori A, Fleischer AB Jr. Indoor tanning relieves pain. Photodermatol Photoimmunol Photomed 2005; 21:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/65\">",
"      Taylor SL, Kaur M, LoSicco K, et al. Pilot study of the effect of ultraviolet light on pain and mood in fibromyalgia syndrome. J Altern Complement Med 2009; 15:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/66\">",
"      Hillhouse J, Stapleton J, Turrisi R. Association of frequent indoor UV tanning with seasonal affective disorder. Arch Dermatol 2005; 141:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/67\">",
"      Nolan BV, Taylor SL, Liguori A, Feldman SR. Tanning as an addictive behavior: a literature review. Photodermatol Photoimmunol Photomed 2009; 25:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/68\">",
"      Kourosh AS, Harrington CR, Adinoff B. Tanning as a behavioral addiction. Am J Drug Alcohol Abuse 2010; 36:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/69\">",
"      Harrington CR, Beswick TC, Leitenberger J, et al. Addictive-like behaviours to ultraviolet light among frequent indoor tanners. Clin Exp Dermatol 2011; 36:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/70\">",
"      Kaur M, Liguori A, Lang W, et al. Induction of withdrawal-like symptoms in a small randomized, controlled trial of opioid blockade in frequent tanners. J Am Acad Dermatol 2006; 54:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/71\">",
"      Gambichler T, Bader A, Vojvodic M, et al. Plasma levels of opioid peptides after sunbed exposures. Br J Dermatol 2002; 147:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/72\">",
"      Mosher CE, Danoff-Burg S. Addiction to indoor tanning: relation to anxiety, depression, and substance use. Arch Dermatol 2010; 146:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/73\">",
"      Demierre MF, Merlino G. Chemoprevention of melanoma. Curr Oncol Rep 2004; 6:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/74\">",
"      Demierre MF, Nathanson L. Chemoprevention of melanoma: an unexplored strategy. J Clin Oncol 2003; 21:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/75\">",
"      Freeman SR, Drake AL, Heilig LF, et al. Statins, fibrates, and melanoma risk: a systematic review and meta-analysis. J Natl Cancer Inst 2006; 98:1538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/76\">",
"      Moan J, Porojnicu AC, Dahlback A, Setlow RB. Addressing the health benefits and risks, involving vitamin D or skin cancer, of increased sun exposure. Proc Natl Acad Sci U S A 2008; 105:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/77\">",
"      Berwick M, Armstrong BK, Ben-Porat L, et al. Sun exposure and mortality from melanoma. J Natl Cancer Inst 2005; 97:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/78\">",
"      Colston K, Colston MJ, Feldman D. 1,25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology 1981; 108:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/79\">",
"      Evans SR, Houghton AM, Schumaker L, et al. Vitamin D receptor and growth inhibition by 1,25-dihydroxyvitamin D3 in human malignant melanoma cell lines. J Surg Res 1996; 61:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/80\">",
"      Reichrath J, Rech M, Moeini M, et al. In vitro comparison of the vitamin D endocrine system in 1,25(OH)2D3-responsive and -resistant melanoma cells. Cancer Biol Ther 2007; 6:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/81\">",
"      Seifert M, Rech M, Meineke V, et al. Differential biological effects of 1,25-dihydroxyVitamin D3 on melanoma cell lines in vitro. J Steroid Biochem Mol Biol 2004; 89-90:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/82\">",
"      Eisman JA, Barkla DH, Tutton PJ. Suppression of in vivo growth of human cancer solid tumor xenografts by 1,25-dihydroxyvitamin D3. Cancer Res 1987; 47:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/83\">",
"      Yudoh K, Matsuno H, Kimura T. 1alpha,25-dihydroxyvitamin D3 inhibits in vitro invasiveness through the extracellular matrix and in vivo pulmonary metastasis of B16 mouse melanoma. J Lab Clin Med 1999; 133:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/84\">",
"      Asgari MM, Maruti SS, Kushi LH, White E. A cohort study of vitamin D intake and melanoma risk. J Invest Dermatol 2009; 129:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/85\">",
"      Weinstock MA, Stampfer MJ, Lew RA, et al. Case-control study of melanoma and dietary vitamin D: implications for advocacy of sun protection and sunscreen use. J Invest Dermatol 1992; 98:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/86\">",
"      Millen AE, Tucker MA, Hartge P, et al. Diet and melanoma in a case-control study. Cancer Epidemiol Biomarkers Prev 2004; 13:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/87\">",
"      Veier&oslash;d MB, Thelle DS, Laake P. Diet and risk of cutaneous malignant melanoma: a prospective study of 50,757 Norwegian men and women. Int J Cancer 1997; 71:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/88\">",
"      Tang JY, Fu T, Leblanc E, et al. Calcium plus vitamin D supplementation and the risk of nonmelanoma and melanoma skin cancer: post hoc analyses of the women's health initiative randomized controlled trial. J Clin Oncol 2011; 29:3078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/89\">",
"      Bonovas S, Nikolopoulos G, Filioussi K, et al. Can statin therapy reduce the risk of melanoma? A meta-analysis of randomized controlled trials. Eur J Epidemiol 2010; 25:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/90\">",
"      Asgari MM, Maruti SS, White E. A large cohort study of nonsteroidal anti-inflammatory drug use and melanoma incidence. J Natl Cancer Inst 2008; 100:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/91\">",
"      Curiel-Lewandrowski C, Nijsten T, Gomez ML, et al. Long-term use of nonsteroidal anti-inflammatory drugs decreases the risk of cutaneous melanoma: results of a United States case-control study. J Invest Dermatol 2011; 131:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/92\">",
"      Joosse A, Koomen ER, Casparie MK, et al. Non-steroidal anti-inflammatory drugs and melanoma risk: large Dutch population-based case-control study. J Invest Dermatol 2009; 129:2620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/93\">",
"      Johannesdottir SA, Chang ET, Mehnert F, et al. Nonsteroidal anti-inflammatory drugs and the risk of skin cancer: a population-based case-control study. Cancer 2012; 118:4768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18073/abstract/94\">",
"      Moyer VA, on behalf of the U.S. Preventive Services Task Force. Behavioral Counseling to Prevent Skin Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2012.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4842 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-07BE0D3610-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_41_18073=[""].join("\n");
var outline_f17_41_18073=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H49280784\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ULTRAVIOLET RADIATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SUN PROTECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49281224\">",
"      Sunscreen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18054875\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2345165\">",
"      - Labeling and use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H933448\">",
"      Other measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49279486\">",
"      Sun protection and nevi",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18054779\">",
"      General guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Status of sun protection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H933833\">",
"      Vitamin D deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H49280971\">",
"      TANNING BED USE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H49280705\">",
"      CHEMOPREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H932772\">",
"      Vitamin D",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H932779\">",
"      - Dietary vitamin D",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28796151\">",
"      Other agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H49281264\">",
"      PUBLIC HEALTH MEASURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H49280784\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/4842\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/4842|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/51/9019\" title=\"table 1\">",
"      Broad spectrum sunscreens",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/24/42378?source=related_link\">",
"      Cancer prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6569?source=related_link\">",
"      Inherited susceptibility to melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/30/18913?source=related_link\">",
"      Patient information: Sunburn (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/20/23874?source=related_link\">",
"      Patient information: Sunburn (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/60/33729?source=related_link\">",
"      Patient information: Sunburn prevention (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=related_link\">",
"      Risk factors for the development of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/16/16650?source=related_link\">",
"      Screening and early detection of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=related_link\">",
"      Treatment of vitamin D deficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/38/28266?source=related_link\">",
"      Vitamin D insufficiency and deficiency in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_41_18074="Nonepileptic paroxysmal disorders in adolescents and adults";
var content_f17_41_18074=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nonepileptic paroxysmal disorders in adolescents and adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/41/18074/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/41/18074/contributors\">",
"     Thien T Nguyen, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/41/18074/contributors\">",
"     Peter W Kaplan, MB, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/41/18074/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/41/18074/contributors\">",
"     Timothy A Pedley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/41/18074/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/41/18074/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/41/18074/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term epileptic seizure refers to a transient occurrence of signs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symptoms due to abnormally excessive neuronal activity of the brain. Epilepsy is a condition characterized by recurrent seizures.",
"   </p>",
"   <p>",
"    While it is estimated that 0.5 to 1 percent of the population has epilepsy, nearly 25 percent of patients seen in epilepsy clinic and monitoring units do not have epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. It is important for clinicians to recognize these transient nonepileptic events that may resemble seizures in order to avoid unnecessary treatment with antiepileptic drugs and to institute the correct treatment when appropriate.",
"   </p>",
"   <p>",
"    The symptoms of epileptic seizures are diverse. As a result, disorders that might be considered in the differential diagnosis will vary depending on the patient's specific clinical presentation. Clearly, not all of these disorders are considered in any one patient.",
"   </p>",
"   <p>",
"    Nonepileptic paroxysmal events that can be mistaken for epilepsy also differ significantly by age group (",
"    <a class=\"graphic graphic_table graphicRef81289 \" href=\"UTD.htm?31/38/32364\">",
"     table 1",
"    </a>",
"    ). This topic will review those diagnoses in adolescents and young adults. These diagnoses can be classified into six broad categories:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Syncope",
"     </li>",
"     <li>",
"      Psychological disorders",
"     </li>",
"     <li>",
"      Sleep disorders",
"     </li>",
"     <li>",
"      Paroxysmal movement disorders",
"     </li>",
"     <li>",
"      Migraine",
"     </li>",
"     <li>",
"      Miscellaneous neurologic events",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nonepileptic paroxysmal events in other age groups are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24376?source=see_link\">",
"     \"Nonepileptic paroxysmal disorders in infancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29175?source=see_link\">",
"     \"Nonepileptic paroxysmal disorders in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40841?source=see_link&amp;anchor=H16#H16\">",
"     \"Seizures and epilepsy in the elderly patient: Etiology, clinical presentation, and diagnosis\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SYNCOPE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syncope is an abrupt loss of consciousness due to an interruption of energy sources to the brain, usually because of a sudden reduction of cerebral perfusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18682?source=see_link\">",
"     \"Evaluation of syncope in adults\"",
"    </a>",
"    .) It is common to confuse seizure and syncope as the cause of an isolated or episodic loss of consciousness [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/5-8\">",
"     5-8",
"    </a>",
"    ], especially but not exclusively when the episode is not witnessed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;A careful clinical history is important in distinguishing syncope from epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/9\">",
"     9",
"    </a>",
"    ]. Important features are not always volunteered and must be specifically solicited.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical setting - Epileptic seizures and syncope arising from cardiac arrhythmias can occur in any setting and are usually unprovoked [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/10\">",
"       10",
"      </a>",
"      ]. Vasovagal syncope tends to occur in the setting of a strong emotional or painful stimulus, but may also occur with more subtle stimuli, including a hot environment. Reflex syncopes occur with specific stimuli (eg, micturition, cough). Events in the setting of exertion suggest syncope related to structural cardiac disease. Except when caused by a cardiac arrhythmia, it is unusual for syncope to occur when patient is supine.",
"     </li>",
"     <li>",
"      Warning symptoms&nbsp;(aura, prodrome) - In vasovagal syncope, a prodrome of presyncope is the rule. These patients may note lightheadedness, warmth, nausea, and a gradual fading or tunneling of binocular vision. In contrast, symptoms of olfactory hallucinations or deja vu suggest a seizure aura. However, not all epileptic seizures include a seizure aura. Cardiogenic syncope typically occurs without warning.",
"     </li>",
"     <li>",
"      Associated symptoms - Pallor and diaphoresis strongly suggest syncope [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/7\">",
"       7",
"      </a>",
"      ]. However, it is unusual for syncope to be associated with tongue biting, head or eye turning to one side, or hypersalivation; these suggest epileptic seizure [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/7,9,11\">",
"       7,9,11",
"      </a>",
"      ]. Urinary incontinence can occur in both seizures and syncope.",
"     </li>",
"     <li>",
"      Motor activity - While motor activity during an episode of unconsciousness often suggests a seizure diagnosis, brief motor activity, including tonic extension of the trunk and limbs or several clonic jerks, can occur in uncomplicated syncope [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/12\">",
"       12",
"      </a>",
"      ]. The severity of convulsive symptoms in syncope varies from subtle signs that are often overlooked to more dramatic symptoms that mimic an epileptic seizure. Relatively few bystanders witnessing syncopal attacks report convulsive symptoms, but clinicians systematically observing attacks (eg, during tilt table testing, invasive cardiac electrophysiologic testing, blood drawing) describe convulsive symptoms in up to half of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/6,11,13-15\">",
"       6,11,13-15",
"      </a>",
"      ]. Convulsions are more likely to occur with more prolonged and more severe cerebral hypoperfusion [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/5,13\">",
"       5,13",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Electroencephalography (EEG) recordings during syncopal events usually demonstrate generalized slowing followed by high voltage frontal delta activity [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. Flattening of the EEG can follow if cerebral hypoperfusion persists. It is at this stage that nonepileptic, seizure-like movements are most often described. It has been suggested that these movements may represent a brainstem-release phenomenon.",
"      <br/>",
"      <br/>",
"      The combination of seizure-like motor activity in the setting of syncope is sometimes referred to as convulsive syncope. While these convulsions are common in syncope, a true epileptic seizure (\"anoxic seizure\") is rare, except in susceptible people or those with prolonged cerebral ischemia [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/13,16\">",
"       13,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Recovery of consciousness. Patients usually wake up quickly after a syncopal event. Prolonged confusion or lethargy lasting several minutes or longer favors seizure [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Causes",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vasovagal syncope is the most prevalent cause of syncope [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/17\">",
"       17",
"      </a>",
"      ]. This often occurs in response to clinical setting (eg, painful procedures, blood drawing, warm setting). In susceptible individuals, autonomic activation leads to a hyperactive parasympathetic cardioinhibitory response",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a diminished sympathetic response leading to vasodepression and syncope. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=see_link\">",
"       \"Reflex syncope\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiogenic syncope related to either tachy- or bradyarrhythmias is less common but carries a more ominous prognosis. These events are usually unprovoked. Structural heart disease (eg, aortic stenosis) can also lead to syncope by obstructing blood flow. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5272?source=see_link&amp;anchor=H5#H5\">",
"       \"Pathogenesis and etiology of syncope\", section on 'Cardiac arrhythmias'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In rare cases, epileptic seizures can induce a cardiac arrhythmia. The most commonly described of these phenomena is an ictal bradycardia in the setting of a temporal lobe seizure [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1128?source=see_link\">",
"       \"Sudden unexpected death in epilepsy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hyperventilation with hypocapnia can also lead to syncope [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. In this age group, this is most commonly seen in the setting of a panic attack. The presumed mechanism involves respiratory alkalosis causing cerebral vasoconstriction, which in turn decreases cerebral blood flow, causing syncope. Patients often have prodromal complaints of dyspnea, circumoral or acral paresthesias, and visual phosphenes. Tetany, muscle cramps, carpopedal spasm, and chest pain can also occur. A three-minute trial of hyperventilation may induce similar symptoms and aid in diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Panic attacks'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Orthostatic hypotension is more common in the elderly than in younger adults, but should be excluded when convulsive syncope is considered in the differential diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/22\">",
"       22",
"      </a>",
"      ]. Orthostatic hypotension is defined by as a systolic blood pressure decrease of at least 20 mmHg or a diastolic blood pressure decrease of at least 10 mmHg after three minutes of standing. Syncope occurs in the setting of either prolonged standing or a sudden assumption of upright posture. In a first attack, acute blood loss should be excluded. Autonomic neuropathy from diabetes and antihypertensive drugs are some of the more common causes of recurrent episodes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/41/12951?source=see_link\">",
"       \"Mechanisms, causes, and evaluation of orthostatic and postprandial hypotension\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Reflex syncope (eg, micturition and cough syncope, carotid sinus hypersensitivity) refers to events that are believed to reflect vagal hypersensitivity to specific stimuli [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/16\">",
"       16",
"      </a>",
"      ]. These diagnoses are suggested by the specific provocation under which they occur. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5272?source=see_link\">",
"       \"Pathogenesis and etiology of syncope\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features described above are helpful in distinguishing syncope from seizure. One study found that, among 539 patients in whom all clinical data could be determined, a point score rating these features correctly classified 94 percent of patients as to syncope versus seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/7\">",
"     7",
"    </a>",
"    ]. However, in many cases, these features are unclear or equivocal, and testing is required.",
"   </p>",
"   <p>",
"    After a generalized tonic-clonic seizure, creatine kinase levels are often elevated, and may remain so for several hours or a day. This is unusual in syncope, unless the event was associated with myocardial infarction, in which case the CK elevations are proportionately greater in the MB isoenzyme fraction, rather than the MM fraction, reflecting cardiac rather than skeletal muscle. Serum prolactin levels, however, are not a useful test to distinguish between syncope and seizure, as elevations can occur in either. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25753?source=see_link&amp;anchor=H22#H22\">",
"     \"Evaluation of the first seizure in adults\", section on 'Prolactin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While an interictal EEG has limited utility in differentiating syncope and epileptic seizure, EEG monitoring can be helpful, especially if an ictus is captured. This usually requires recurrent events and prolonged EEG and ECG monitoring.",
"   </p>",
"   <p>",
"    Other testing that can be helpful in the differentiating syncope from seizures include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tilt table testing can provoke vasovagal syncope and provide support for this diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/6,23\">",
"       6,23",
"      </a>",
"      ]. Confirmation that the induced spell is representative of the episode(s) being evaluated can help avoid a false positive diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=see_link\">",
"       \"Reflex syncope\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      ECG or Holter monitoring can be helpful in identifying cardiac arrhythmias which can lead to syncope [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/6\">",
"       6",
"      </a>",
"      ]. In rare patients with epilepsy and arrhythmia, combined EEG and ECG monitoring can be useful to identify the primary event [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/18\">",
"       18",
"      </a>",
"      ]. Long-term cardiac monitoring techniques can be used for patients with infrequent, recurrent attacks. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36361?source=see_link\">",
"       \"Ambulatory monitoring in the assessment of cardiac arrhythmias\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnostic evaluation of a patient with suspected syncope is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18682?source=see_link\">",
"     \"Evaluation of syncope in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PSYCHOLOGICAL DISORDERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Psychogenic nonepileptic seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among series of patients undergoing video-EEG monitoring, the most common disorder mistaken for epilepsy is psychogenic nonepileptic seizures (PNES) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/1\">",
"     1",
"    </a>",
"    ]. While often categorized under somatoform or dissociative disorders, PNES probably have a heterogeneous psychiatric pathogenesis. Patients display episodes that superficially resemble epileptic seizures, but are often atypical in one or more of their features (",
"    <a class=\"graphic graphic_table graphicRef77773 \" href=\"UTD.htm?5/53/5980\">",
"     table 2",
"    </a>",
"    ). Video-EEG monitoring is usually required for diagnosis.",
"   </p>",
"   <p>",
"    PNES are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33226?source=see_link\">",
"     \"Psychogenic nonepileptic seizures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Panic attacks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Panic attacks usually occur in individuals with an underlying anxiety disorder. Attacks are variable in duration (minutes to hours) and can include palpitations, dyspnea, chest pain, presyncope, and a sense of impending doom. Patients often manifest hyperventilation, tachycardia, diaphoresis, and tremulousness during the attack. In rare circumstances, hyperventilation can lead to a brief loss of consciousness [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Causes'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    When not clearly precipitated by stressful circumstances or when associated with feelings of depersonalization or derealization, panic attacks may be mistaken for seizures. Similarly, seizures can be mistaken for panic attacks because anxiety is a common comorbid condition in individuals with epilepsy, and fear can be an ictal symptom, particularly in temporal lobe epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/1/23578?source=see_link&amp;anchor=H8#H8\">",
"     \"Localization-related (partial) epilepsy: Causes and clinical features\", section on 'Mesial temporal lobe epilepsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Features which help distinguish epileptic seizures from panic attacks include their short duration (less than two minutes), stereotyped nature, abrupt onset, motor automatisms, unresponsiveness, and postictal lethargy, all of which are atypical for panic attacks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7305?source=see_link\">",
"     \"Pharmacotherapy for panic disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Episodic dyscontrol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with episodic dyscontrol, also called intermittent explosive disorder (IED), display episodes of rage and violence. This disorder usually presents in teenagers and young adults, although it can occur in younger children as well [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/26\">",
"     26",
"    </a>",
"    ]. Behavior exhibited during these episodes can appear as though the individual is \"out of control.\" Other features of the episodes that resemble epileptic seizures include their abrupt onset, often without apparent precipitant, and their short duration, often followed by fatigue and remorse. However, the directed violence of these episodes is rarely a feature of epileptic seizures.",
"   </p>",
"   <p>",
"    There is a somewhat high prevalence of nonspecific EEG abnormalities in patients with IED, perhaps reflecting an underlying brain pathology, however, a neurobiologic mechanism of this disorder is not defined [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SLEEP DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of their episodic and often paroxysmal nature, parasomnias and other sleep disorders may be confused with epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/28\">",
"     28",
"    </a>",
"    ]. An exclusive night-time occurrence of events may suggest a sleep disorder, but does not exclude epilepsy, as this is a characteristic of certain epileptic disorders such as nocturnal frontal lobe epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/11,29\">",
"     11,29",
"    </a>",
"    ]. The two disorders can also co-occur. In one case series, parasomnias were found to be prevalent in patients with nocturnal frontal lobe epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/1/23578?source=see_link&amp;anchor=H12#H12\">",
"     \"Localization-related (partial) epilepsy: Causes and clinical features\", section on 'Frontal lobe epilepsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Specific disorders",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Narcolepsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Narcolepsy is a rare sleep disorder associated with rapid eye movement (REM) sleep invading normal wakefulness. The tetrad of clinical features includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Excessive daytime sleep",
"      </strong>",
"      - Irresistible sleepiness can culminate in a \"sleep attack,\" in which sleep onset can occur while talking, driving, or walking.",
"     </li>",
"     <li>",
"      <strong>",
"       Cataplexy",
"      </strong>",
"      - This sudden loss of muscle tone with preserved consciousness can be mistaken for an atonic seizure. This can result in falls and brief paralysis, but more often is limited to buckling of the knees and slurring of speech. The attacks are classically precipitated by strong emotion, most commonly laughter, but also anger, fear, surprise, or excitement; this feature helps distinguish these attacks from an epileptic seizure.",
"     </li>",
"     <li>",
"      <strong>",
"       Sleep paralysis",
"      </strong>",
"      - An inability to move or speak, sleep paralysis typically occurs upon awakening or falling asleep and lasts less than 10 minutes. Sometimes, the episodes resolve when someone touches the patient. These can be very frightening to the patient who maintains consciousness throughout the event.",
"     </li>",
"     <li>",
"      <strong>",
"       Hypnagogic hallucinations",
"      </strong>",
"      - This is usually a visual and less often a somatosensory, auditory, vestibular, or olfactory hallucination that occurs while falling asleep or on awakening. The content can be simple (a brief image of a face) or complex (an entire scene occurring in the room). The patient is fully aware during the episode. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Etiologies'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Only 10 to 15 percent of patients with narcolepsy experience all of these symptoms. When daytime sleep attacks, cataplexy, hypnagogic hallucinations, and sleep paralysis occur as isolated features, they may be mistaken for epilepsy and vice versa [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. Polysomnography and a multiple sleep latency test (MSLT) aids in the diagnosis, showing decreased sleep latency and decreased REM latency in patients with narcolepsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25913?source=see_link\">",
"     \"Clinical features and diagnosis of narcolepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Nocturnal paroxysmal dystonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nocturnal paroxysmal dystonia or paroxysmal hypnogenic dyskinesia is a name originally given to repeated dystonic or dyskinetic episodes that occurred during or immediately after arousal from non-REM sleep, more rarely, during wakefulness [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. These episodes typically last less than one minute, sometimes up to one hour, and often recur several times per night. The movements are often violent and may result in injury to the patient or bed partner. Patients do not recall the events.",
"   </p>",
"   <p>",
"    This condition has been reported in children and adults, can be isolated or familial, and is persistent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. These episodes are often not associated with epileptiform EEG activity or other abnormal EEG findings. However, findings of epileptiform activity on zygomatic and sphenoidal leads and response to antiepileptic drugs in some patients suggest that this disorder is of epileptic origin, a manifestation of nocturnal frontal lobe epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/29,36\">",
"     29,36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/1/23578?source=see_link&amp;anchor=H12#H12\">",
"     \"Localization-related (partial) epilepsy: Causes and clinical features\", section on 'Frontal lobe epilepsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Periodic limb movements of sleep and restless legs syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Restless legs syndrome (RLS) refers to symptoms of discomfort in the legs that occur at rest and are relieved by movement [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. RLS is frequently associated with involuntary, jerking movements of the legs during sleep, known as periodic leg movements of sleep (PLMS). The movements are typically characterized by toe extension and flexion at the ankle, knee, and hip and occur at periodic intervals of 20 to 40 seconds, which is unlike an epileptic seizure [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/35,39\">",
"     35,39",
"    </a>",
"    ]. PLMS occasionally involves the arms but does not include vocalizations or facial movements.",
"   </p>",
"   <p>",
"    PLMS usually occur in stage 1 and 2 of sleep, early in the night, in clusters lasting minutes to hours. Patients are usually unaware of the movements, which are often more bothersome to the bed partner. Polysomnography",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    EEG monitoring may aid in the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32554?source=see_link\">",
"     \"Restless legs syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Sleep starts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most people have experienced a sudden jerking movement upon falling asleep, often accompanied by a subjective sensation of falling. This phenomenon, also known as benign hypnic myoclonus or sleep starts, is usually easily recognized [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/35,40\">",
"     35,40",
"    </a>",
"    ]. Rarely, hypnic myoclonus can become unusually violent, very frequent, or repetitive, and confused for myoclonic seizures or even tonic-clonic seizures. The phenomenon is restricted to sleep, and always or virtually always in the transition between sleep and wakefulness, and is not associated with other phenomena. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4711?source=see_link\">",
"     \"Nocturnal leg cramps\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Rhythmic movement disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhythmic movements such as nocturnal head banging, body rocking, and head rolling typically occur in young children as they try to fall asleep [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/40\">",
"     40",
"    </a>",
"    ]. Episodes usually resolve by five years of age, but can persist into adult life [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29175?source=see_link&amp;anchor=H10#H10\">",
"     \"Nonepileptic paroxysmal disorders in children\", section on 'Sleep disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Sleep walking and night terrors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brief nocturnal arousals occurring during non-REM sleep can manifest as confusional arousals, sleep walking, and night terrors. These conditions are most common in children between 4 and 12 years of age and usually resolve during late adolescence. However, sometimes symptoms persist into adulthood, and up to 10 percent of cases begin in adolescence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29175?source=see_link&amp;anchor=H10#H10\">",
"     \"Nonepileptic paroxysmal disorders in children\", section on 'Sleep disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Diagnostic approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific features of the events, including duration, frequency, timing, stereotypy, and vocalizations can help distinguish nocturnal seizures from sleep disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/35\">",
"     35",
"    </a>",
"    ]. In contrast to events arising from a sleep disorder, nocturnal seizures are typically brief (1 to 2 minutes), and arise out of stage II sleep, often shortly after sleep onset. Nocturnal epileptic seizures often recur in clusters at night, and are very stereotyped. It is unusual for epileptic seizures to include clearly-articulated vocalizations or complex, directed motor activity. Individually, these features are neither specific nor sensitive [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/35,43\">",
"     35,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A questionnaire that includes these features and scores their presence or absence according to likelihood of epileptic seizures was been developed and validated in a sample of 62 patients with paroxysmal nocturnal events [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/43\">",
"     43",
"    </a>",
"    ]. This Frontal Lobe Epilepsy and Parasomnias (FLEP) Scale assigns positive points to clinical items favoring epilepsy (duration &lt; 2 minutes; multiple events per night; occurrence within first 30 minutes of sleep; preceding aura; dystonic posturing; stereotyped events; lucid speech and recall of event) and negative points to items favoring a sleep disorder (age &gt;55 years, event duration &gt; 10 minutes, wandering outside of bedroom during event, complicated behaviors during event, highly variable events, coherent speech during event with impaired recall). In this study, the FLEP scale was found to have a sensitivity of 100 percent and a specificity of 90 percent for a diagnosis of epilepsy when compared with video-electroencephalogram monitoring. However, another study in 71 patients found a lower sensitivity and specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/44\">",
"     44",
"    </a>",
"    ]. In particular, REM sleep behavior disorder was often mistaken for epilepsy, and patients with nocturnal frontal lobe epilepsy frequently reported episodes of wandering that suggested a parasomnia. Recording episodes on video-EEG and polysomnography remains necessary when the diagnosis is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/29,35\">",
"     29,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     MOVEMENT DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperkinetic movement disorders or dyskinesias include chorea, dystonia, athetosis, tics, tremors, and ballism. These are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18058?source=see_link\">",
"     \"Hyperkinetic movement disorders in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Movement disorders are rarely confused with seizures if the motor activity is classic in appearance and is sustained rather than episodic. Also, impaired consciousness does not occur with movement disorders, and when present, strongly suggests seizures. However, confusion can arise when movement disorders present with episodic symptoms, and when focal epileptic seizures are characterized by isolated dystonic posturing or have continuous symptoms (epilepsia partialis continua). Some patients with dystonia and other movement disorders may obtain symptomatic relief from sensory tricks, such as lightly touching their face to ameliorate cervical dystonia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/45\">",
"     45",
"    </a>",
"    ]. This phenomenon is known as geste antagoniste and may be a useful feature distinguishing dystonic movements from epilepsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Paroxysmal dyskinesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;These paroxysmal movement disorders are classified according to the setting in which they occur and can include a variety of movements including dystonia, ballism and chorea [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. The mechanism responsible for paroxysmal dyskinesia is unknown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18058?source=see_link&amp;anchor=H10#H10\">",
"     \"Hyperkinetic movement disorders in children\", section on 'Paroxysmal dyskinesia with dystonia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of these disorders is based in large part on history. A video EEG recording of events is invaluable in difficult cases.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Paroxysmal kinesigenic dyskinesia (PKD) consists of brief (less than one minute) attacks of choreoathetosis, dystonia, or both, which are precipitated by sudden changes in movement; getting up from a chair and getting out of a car are frequent triggers [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/47,48\">",
"       47,48",
"      </a>",
"      ]. Movements are often unilateral but may be bilateral. Consciousness is retained. Many individuals may have a brief, nonspecific warning or aura prior to an attack. The interictal examination is normal. PKD may be a familial,",
"      <span class=\"nowrap\">",
"       sporadic/idiopathic,",
"      </span>",
"      or secondary condition (due to multiple sclerosis, stroke, traumatic brain injury). Men are affected more often than women, with an estimated ratio of 3 to 4:1.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       Carbamazepine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      is often highly effective [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Paroxysmal nonkinesigenic dyskinesia consists of attacks of spontaneous, severe dystonia that may be precipitated by alcohol, caffeine, and stress [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/46,49\">",
"       46,49",
"      </a>",
"      ]. These episodes last two minutes to several hours, and sometimes two days. Antiepileptic medications can be efficacious, but less consistently than in PKD. Familial, sporadic, and secondary forms have been described.",
"     </li>",
"     <li>",
"      Paroxysmal exercise-induced dyskinesia consists of brief episodes of dystonia that occur after several minutes of exercise, not at initiation of movement as in PKD [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/46,49\">",
"       46,49",
"      </a>",
"      ]. Typically, the part of the body that has been doing the most exercise becomes dystonic. The abnormal movement resolves gradually with cessation of the exercise. This may be a sporadic or hereditary condition. In general, antiepileptic drugs are not helpful.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"       Acetazolamide",
"      </a>",
"      has been effective in some families.",
"     </li>",
"     <li>",
"      Paroxysmal hypnogenic dyskinesia or nocturnal paroxysmal dystonia consists of dystonic or dyskinetic episodes during or immediately after arousal from non-REM sleep or, more rarely, during wakefulness. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Nocturnal paroxysmal dystonia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Tics and stereotypies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tics are relatively brief, sudden, rapid, and intermittent movements (motor tics) or sounds (vocal tics). They may be repetitive and stereotypic. Tics are usually abrupt in onset and brief (clonic tics) but may be slow and sustained (dystonic tics). Tics are associated with a premonitory feeling that is relieved by performing the tics. Unlike other hyperkinetic dyskinesias and unlike epileptic seizures, tics may be temporarily suppressed. Tics also differ from epilepsy by the variability of the movement and the urge to perform tics. The myoclonic jerks of juvenile myoclonic epilepsy can be mistaken for tics, but these cannot be suppressed, have no premonitory sensation, and are quicker and more stereotyped [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/30/15849?source=see_link&amp;anchor=H88578549#H88578549\">",
"     \"Juvenile myoclonic epilepsy\", section on 'Seizures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tics can occur as part of Tourette's syndrome, but may also be an isolated phenomenon. More clinical details about the evaluation and treatment of a patient with tics is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22664?source=see_link&amp;anchor=H4#H4\">",
"     \"Tourette syndrome\", section on 'Tics'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22664?source=see_link&amp;anchor=H8#H8\">",
"     \"Tourette syndrome\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22664?source=see_link&amp;anchor=H10#H10\">",
"     \"Tourette syndrome\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Stereotypies are repetitive, purposeless actions such as head banging, head rolling, body rocking, and hand flapping [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/51\">",
"     51",
"    </a>",
"    ]. Similar to tics, stereotypies may be consciously suppressed and decreased by distraction. Unlike tics, stereotypies are not preceded by a progressive urge or relief following the activities. Often, they manifest as self-stimulating behaviors in response to tension and anxiety and may comfort the patient. Stereotypies may occur alone or may be secondary to trauma, drugs (eg, chronic amphetamine abuse), or toxic-metabolic insult. These movements can be seen in normal individuals, but are more common in those with schizophrenia, mental retardation, and autism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18058?source=see_link&amp;anchor=H15#H15\">",
"     \"Hyperkinetic movement disorders in children\", section on 'Stereotypies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Hemifacial spasm, blepharospasm, and Meige syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemifacial spasm is characterized by involuntary synchronous spasms of one side of the face, usually beginning around the eye. They are typically brief, irregular clonic movements but are occasionally tonic. The disorder almost always presents unilaterally, although bilateral involvement may occur in severe cases (less than 5 percent overall) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/52\">",
"     52",
"    </a>",
"    ]. Brief clonic movements are first noted in the orbicularis oculi and spread over months to years to involve other facial muscles. It never involves muscles other than those innervated by the facial nerve. Patients cannot suppress the movements. Unlike other movement disorders, this can continue during sleep. Onset is most commonly in midlife. Complete remission is rare. Neurovascular compression of the ipsilateral facial nerve is evident in 88 to 93 percent of magnetic resonance imaging studies [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/53\">",
"     53",
"    </a>",
"    ]. Botulinum toxin injections are the most effective treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7689?source=see_link&amp;anchor=H7#H7\">",
"     \"Classification and evaluation of myoclonus\", section on 'Peripheral'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6537?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of myoclonus\", section on 'Botulinum toxin injections'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Blepharospasm is a focal dystonia characterized by involuntary contractions of the orbicularis oculi muscles, resulting in the bilateral closure of the eyes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/55\">",
"     55",
"    </a>",
"    ]. This can range from a relatively benign increase in blink frequency to sustained eyelid closure and functional blindness. Onset is gradual and usually occurs in midlife. The etiology of blepharospasm is unknown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/60/970?source=see_link&amp;anchor=H9#H9\">",
"     \"Classification and evaluation of dystonia\", section on 'Blepharospasm'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Meige syndrome or craniocervical dystonia encompasses the dystonic contractions of blepharospasm in addition to spasms of the lower facial muscles, jaw, and neck. Both blepharospasm and Meige syndrome may involve bilateral facial muscle contractions. Most cases have no known etiology. However, these symptoms can be seen as a result of chronic neuroleptic medication.",
"   </p>",
"   <p>",
"    When unilateral, these conditions can be mistaken for epilepsia partialis continua, and vice versa [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. A routine EEG is usually sufficient for diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Stiff-person syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stiff-person syndrome is characterized by sudden muscle stiffness with superimposed painful cramps. It predominantly affects the axial and proximal limb muscles and is aggravated by emotional, somatosensory, or acoustic stimuli. Startle-induced spasms are common and may be mistaken for stimulus-induced seizures. However, the presence of pain and the sustained spasms with muscle rigidity between spasms are not typical for epilepsy.",
"   </p>",
"   <p>",
"    Stiff-person syndrome is frequently associated with antibodies to glutamic acid decarboxylase or amphiphysin. EMG may be helpful in the diagnosis, usually showing continuous low-frequency firing of normal motor action potentials without the ability of voluntary relaxation. EEG is normal [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/41/665?source=see_link\">",
"     \"Stiff-person syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     MIGRAINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both migraine and epilepsy are characterized by episodes of neurologic dysfunction that are accompanied by headache, as well as gastrointestinal, autonomic, and psychological features. Clinical features common to both migraine and epilepsy include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Headache is a cardinal feature of migraine, but is also a common postictal event, reported in 40 to 45 percent of both pediatric and adult patients with epilepsy [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/60-70\">",
"       60-70",
"      </a>",
"      ]. This postictal headache often has migrainous features, can last more than a few hours, and occurs after both partial and generalized seizures. At the same time, a third or more of patients with migraine do not have headache with at least some of their migraine events [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/71\">",
"       71",
"      </a>",
"      ]. Sometimes called migraine dissoci&eacute;, the confidence in making this diagnosis is considerably higher if the patient has previously had similar episodes associated with headaches. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=see_link&amp;anchor=H222097321#H222097321\">",
"       \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\", section on 'Migraine aura without headache'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Visual aura is a feature of classic migraine and occipital epilepsy. In both disorders, simple hallucinations are more common than complex; the images are binocular and often spread or move. Epileptic visual auras tend to include highly colored, circular or spherical images that move rapidly, are stereotyped, and are relatively brief (a few minutes or less) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/61-63\">",
"       61-63",
"      </a>",
"      ]. In contrast, migrainous auras are more linear or geometric in appearance, tend to build and spread over several minutes, and last several minutes to an hour. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/36/42569?source=see_link&amp;anchor=H7#H7\">",
"       \"Approach to the patient with visual hallucinations\", section on 'Migraine'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/36/42569?source=see_link&amp;anchor=H8#H8\">",
"       \"Approach to the patient with visual hallucinations\", section on 'Seizures'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Somatosensory symptoms can occur in both migraine and seizures. As with the visual aura, in migraine, symptoms spread slowly over several minutes to an hour, while in seizures, the symptoms spread quickly and rarely last more than a few minutes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=see_link&amp;anchor=H203275055#H203275055\">",
"       \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\", section on 'Migraine aura'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Auditory symptoms are a rare manifestation of migraine and epilepsy. In migraine, these are unformed, ringing, clicking, buzzing, humming, hissing, rumbling, or growling noises [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/72\">",
"       72",
"      </a>",
"      ]. In epileptic aura, auditory symptoms range from unformed to complex (eg, voices, music), but again are brief and stereotyped compared with migraine [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/73\">",
"       73",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Hallucinations'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Motor activity and loss of consciousness during an episode is unusual for migraine and suggests epilepsy. Prolonged confusion or lethargy after an attack favors epilepsy but can occur in some forms of migraine, especially basilar artery migraine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/44/44743?source=see_link\">",
"     \"Basilar-type migraine\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     HALLUCINATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hallucinations are the perception of an external sensory stimulus where none exists. These can be somatosensory, visual, auditory, and olfactory. Hallucinations can be part of a seizure aura but can also occur as episodic phenomena in a variety of other conditions. In general, these conditions can be distinguished from each other by the nature of the hallucination and accompanying clinical features.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Somatosensory hallucinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatosensory or haptic hallucinations include external tactile sensations and internal bodily feelings. The former may be described as pain, itching, tingling, and electric shock sensations. Internal feelings include deep pain, nausea and other visceral sensations, and sexual pleasure. Patients may sense that a limb or joint is being moved when it is not.",
"   </p>",
"   <p>",
"    Visceral hallucinations, such as the feeling of gastric rising, are a common aura in temporal lobe epilepsy. More superficial sensory symptoms of an epileptic aura tend to be lateralized. They may be stationary or they may \"march\" or spread over a several seconds to a few minutes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Visual hallucinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visual hallucinations are a clinical manifestation of neuroophthalmologic dysfunction resulting from a wide variety of underlying etiologies. These can be simple (eg, lights, colors, lines, shapes, or geometric designs) or complex (images of people, animals, objects, or a lifelike scene).",
"   </p>",
"   <p>",
"    Causes of visual hallucinations include release hallucinations associated with vision loss (Charles Bonnet syndrome), epilepsy, migraine, and neurodegenerative disease, among others. These can generally be distinguished by specific clinical features including simple versus complex imagery, monocular versus binocular involvement, triggers, duration, insight, and associated symptoms and signs (",
"    <a class=\"graphic graphic_table graphicRef73106 \" href=\"UTD.htm?23/49/24349\">",
"     table 3",
"    </a>",
"    ). This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/36/42569?source=see_link\">",
"     \"Approach to the patient with visual hallucinations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Auditory hallucinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Auditory hallucinations can also arise from injury to any portion of the peripheral and central auditory pathways. As with visual hallucinations, these may be simple and unformed (static, beeping, humming) or may be more complex (voices, music).",
"   </p>",
"   <p>",
"    Auditory hallucinations are most strongly linked to schizophrenia, for which it is a core symptom, but are also described in patients with Alzheimer disease and patients with epilepsy, as well as in normal individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/74,75\">",
"     74,75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Auditory hallucinations are an uncommon manifestation of epilepsy (less than two percent of cases) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/73,76\">",
"     73,76",
"    </a>",
"    ]. Simple or unformed epileptic auditory auras or auditory distortions (hypacusis or hyperacusis) are often lateralized [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/77\">",
"     77",
"    </a>",
"    ]. Complex, formed auditory hallucinations, such as voices or music, are less common and may be produced by seizures arising from the temporal association or limbic areas. These are often considered psychic rather than auditory, because of associated experiential phenomena (eg, deja vu) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/73,78\">",
"     73,78",
"    </a>",
"    ]. Musical hallucinations most often occur with nondominant hemispheric foci. Prominent auditory hallucinations are a feature of a genetic syndrome, autosomal dominant partial epilepsy with auditory features or familial lateral temporal lobe epilepsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/1/23578?source=see_link&amp;anchor=H5#H5\">",
"     \"Localization-related (partial) epilepsy: Causes and clinical features\", section on 'Genetic syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Olfactory hallucinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Olfactory hallucinations are particularly associated with epilepsy, but can also occur in neurodegenerative disease and in psychiatric conditions. When of epileptic origin, the seizure origin is in the temporal lobe. The hallucination is perceived as intense and foul, but is often otherwise ill-described. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/1/23578?source=see_link&amp;anchor=H8#H8\">",
"     \"Localization-related (partial) epilepsy: Causes and clinical features\", section on 'Mesial temporal lobe epilepsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dysosmia, an altered sense of smell, most often results from a local nasopharyngeal process such as toxin exposure, physical irritant, or medication effect. The abnormal smell perception may appear episodic when it occurs only when certain airborne aromatic molecules interact with the injured receptors. As a result dysosmia can appear unprovoked, random, and recurrent and as such, may be reported as an olfactory hallucination [",
"    <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/79\">",
"     79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13801?source=see_link\">",
"     \"Anatomy and etiology of taste and smell disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Etiologies",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An epileptic aura usually produces hallucinations that involve a single sensory modality or multiple sensory modalities in sequence, rather than simultaneously [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/78,80\">",
"       78,80",
"      </a>",
"      ]. Olfactory hallucinations may be the best known, but are actually less common than visual, somatosensory, and auditory auras [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/25,81\">",
"       25,81",
"      </a>",
"      ]. While these hallucinations have some localizing value, they are not reliable in pinpointing the focus of seizure onset. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/1/23578?source=see_link\">",
"       \"Localization-related (partial) epilepsy: Causes and clinical features\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In general, epileptic auras are best distinguished from other causes of hallucinations by their paroxysmal onset, brevity (less than 2 minutes), and their stereotyped recurrence. It is also unusual for a hallucination to be the sole manifestation of epilepsy in any given patient; these typically occur as seizure auras, followed by other ictal manifestations [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/78,80\">",
"       78,80",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Schizophrenia and psychotic depression are usually associated with auditory hallucinations [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/82\">",
"       82",
"      </a>",
"      ]. While other sensory modalities may be involved, auditory hallucinations are usually also present. Distinguishing features of these hallucinations include their personal (often sinister) meaning for the patient who usually lacks insight as to their unreal nature [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/83,84\">",
"       83,84",
"      </a>",
"      ]. These hallucinations are less episodic and more prolonged than in other disorders. Patients generally have a clear sensorium (are awake and alert) and manifest other psychotic features (delusions and other abnormal thought content).",
"     </li>",
"     <li>",
"      Hypnagogic and hypnopompic hallucinations are classically associated with narcolepsy, but are also common in normal individuals who do not manifest other features of this disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/79\">",
"       79",
"      </a>",
"      ]. These are often multimodality hallucinations with congruent visual, auditory, and tactile sensations that are complex and realistic. Insight is usually retained [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/79,85\">",
"       79,85",
"      </a>",
"      ]. Duration and frequency are variable. The distinguishing feature in these episodes is their invariable occurrence just before falling asleep or just after awakening. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/36/42569?source=see_link&amp;anchor=H12#H12\">",
"       \"Approach to the patient with visual hallucinations\", section on 'Narcolepsy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neurodegenerative disease, particularly dementia with Lewy bodies, but also Parkinson disease, and less often Alzheimer disease, can be associated with hallucinations, usually visual [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/86\">",
"       86",
"      </a>",
"      ]. The visual imagery is typical complex and insight is usually retained. Other manifestations of the disease (eg, parkinsonism, cognitive impairment) are present. Tactile and olfactory hallucinations are less common but have been reported in Parkinson disease [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/87-89\">",
"       87-89",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Migraine is frequently associated with visual aura. Tactile and, less commonly, auditory hallucinations have also been described in migraine. Characteristic features of migrainous hallucinations include a typical duration of several minutes to an hour or two and that they are usually followed by a headache with typical migrainous features. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Migraine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Withdrawal states such as delirium tremens and",
"      <strong>",
"       intoxication",
"      </strong>",
"      with amphetamines, cocaine, phencyclidine,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/26/5542?source=see_link\">",
"       chloral hydrate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      can be associated with multimodality hallucinations. These states may cause formication, a feeling of ants crawling under the skin, along with complex visual and auditory hallucinations [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/90\">",
"       90",
"      </a>",
"      ]. Patients usually exhibit agitation, confusion, and autonomic activity (tremulousness, tachycardia, diaphoresis). Many other drugs are associated with visual hallucinations (",
"      <a class=\"graphic graphic_table graphicRef51079 \" href=\"UTD.htm?29/58/30635\">",
"       table 4",
"      </a>",
"      ). Isolated auditory hallucinations have been described with salicylates, marijuana, valproate,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"       pentoxifylline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/25/19862?source=see_link\">",
"       cyproheptadine",
"      </a>",
"      , beta-blockers, tricyclic antidepressants, and benzodiazepines, usually in the setting of intoxication [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/72,91\">",
"       72,91",
"      </a>",
"      ]. Sexual hallucinations can occur during or after sedation, especially with newer anesthetic agents such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"       midazolam",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"       propofol",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/92\">",
"       92",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Delirium may be produced by metabolic abnormalities as well as by drug intoxication or withdrawal and is characterized by a clouded sensorium along with (in order of prevalence) visual, auditory and tactile hallucinations [",
"      <a class=\"abstract\" href=\"UTD.htm?17/41/18074/abstract/93\">",
"       93",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=see_link\">",
"       \"Diagnosis of delirium and confusional states\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/1/36889?source=see_link\">",
"       \"Acute toxic-metabolic encephalopathy in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Focal brain lesions from stroke, multiple sclerosis, and others can produce positive sensory symptoms, usually depending on the represented sensory modality. These are often restricted anatomically. Examples include complex hemifield visual hallucinations with occipital lobe lesions and a lateralized thalamic pain syndrome. Peduncular hallucinosis, a phenomenon associated with midbrain lesions, produces complex visual, tactile",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      auditory hallucinations with variable retention of insight. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/36/42569?source=see_link&amp;anchor=H11#H11\">",
"       \"Approach to the patient with visual hallucinations\", section on 'Peduncular hallucinosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic reviews those imitators of epilepsy that are most common in adolescents and adults. Disorders more prevalent in childhood can occasionally present in this age group as well (",
"    <a class=\"graphic graphic_table graphicRef81289 \" href=\"UTD.htm?31/38/32364\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29175?source=see_link\">",
"     \"Nonepileptic paroxysmal disorders in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Older adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;In older patients, episodic neurologic symptoms may also represent transient ischemic attack or transient global amnesia, among others. These are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40841?source=see_link\">",
"     \"Seizures and epilepsy in the elderly patient: Etiology, clinical presentation, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of epileptic seizures in adolescents and adults includes a variety of benign, physiologic phenomena as well as pathologic conditions (",
"    <a class=\"graphic graphic_table graphicRef81289 \" href=\"UTD.htm?31/38/32364\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Clinical features of these events help distinguish these from epileptic seizures (see descriptions of individual disorders above). In difficult cases, electroencephalography (EEG), particularly video-EEG monitoring, is useful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15368?source=see_link\">",
"     \"Video and ambulatory EEG monitoring in the diagnosis of seizures and epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/1\">",
"      Benbadis SR, Allen Hauser W. An estimate of the prevalence of psychogenic non-epileptic seizures. Seizure 2000; 9:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/2\">",
"      Scheepers B, Clough P, Pickles C. The misdiagnosis of epilepsy: findings of a population study. Seizure 1998; 7:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/3\">",
"      Smith D, Defalla BA, Chadwick DW. The misdiagnosis of epilepsy and the management of refractory epilepsy in a specialist clinic. QJM 1999; 92:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/4\">",
"      McDade G, Brown SW. Non-epileptic seizures: management and predictive factors of outcome. Seizure 1992; 1:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/5\">",
"      Gavris MF, Khalighi K, Mascarenhas DA. Idiopathic cardiac asystole presenting as epileptic seizures. J Electrocardiol 2002; 35:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/6\">",
"      Zaidi A, Clough P, Cooper P, et al. Misdiagnosis of epilepsy: many seizure-like attacks have a cardiovascular cause. J Am Coll Cardiol 2000; 36:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/7\">",
"      Sheldon R, Rose S, Ritchie D, et al. Historical criteria that distinguish syncope from seizures. J Am Coll Cardiol 2002; 40:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/8\">",
"      Hoefnagels WA, Padberg GW, Overweg J, Roos RA. Syncope or seizure? A matter of opinion. Clin Neurol Neurosurg 1992; 94:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/9\">",
"      Cooper PN, Westby M, Pitcher DW, Bullock I. Synopsis of the National Institute for Health and Clinical Excellence Guideline for management of transient loss of consciousness. Ann Intern Med 2011; 155:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/10\">",
"      Hadjikoutis S, O'Callaghan P, Smith PE. The investigation of syncope. Seizure 2004; 13:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/11\">",
"      Aminoff MJ, Scheinman MM, Griffin JC, Herre JM. Electrocerebral accompaniments of syncope associated with malignant ventricular arrhythmias. Ann Intern Med 1988; 108:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/12\">",
"      Rodrigues Tda R, Sternick EB, Moreira Mda C. Epilepsy or syncope? An analysis of 55 consecutive patients with loss of consciousness, convulsions, falls, and no EEG abnormalities. Pacing Clin Electrophysiol 2010; 33:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/13\">",
"      Passman R, Horvath G, Thomas J, et al. Clinical spectrum and prevalence of neurologic events provoked by tilt table testing. Arch Intern Med 2003; 163:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/14\">",
"      Lin JT, Ziegler DK, Lai CW, Bayer W. Convulsive syncope in blood donors. Ann Neurol 1982; 11:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/15\">",
"      Lempert T, Bauer M, Schmidt D. Syncope: a videometric analysis of 56 episodes of transient cerebral hypoxia. Ann Neurol 1994; 36:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/16\">",
"      Brenner RP. Electroencephalography in syncope. J Clin Neurophysiol 1997; 14:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/17\">",
"      Britton JW, Benarroch E. Seizures and syncope: anatomic basis and diagnostic considerations. Clin Auton Res 2006; 16:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/18\">",
"      Rossetti AO, Dworetzky BA, Madsen JR, et al. Ictal asystole with convulsive syncope mimicking secondary generalisation: a depth electrode study. J Neurol Neurosurg Psychiatry 2005; 76:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/19\">",
"      Britton JW, Ghearing GR, Benarroch EE, Cascino GD. The ictal bradycardia syndrome: localization and lateralization. Epilepsia 2006; 47:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/20\">",
"      North KN, Ouvrier RA, Nugent M. Pseudoseizures caused by hyperventilation resembling absence epilepsy. J Child Neurol 1990; 5:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/21\">",
"      David JE, Yale SH, Vidaillet HJ. Hyperventilation-induced syncope: no need to panic. Clin Med Res 2003; 1:137.",
"     </a>",
"    </li>",
"    <li>",
"     Low, PA. Clinical autonomic disorders, 2nd ed, Lippincott-Raven, Philadelphia 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/23\">",
"      Eir&iacute;s-Pu&ntilde;al J, Rodr&iacute;guez-N&uacute;&ntilde;ez A, Fern&aacute;ndez-Mart&iacute;nez N, et al. Usefulness of the head-upright tilt test for distinguishing syncope and epilepsy in children. Epilepsia 2001; 42:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/24\">",
"      Chiesa V, Gardella E, Tassi L, et al. Age-related gender differences in reporting ictal fear: analysis of case histories and review of the literature. Epilepsia 2007; 48:2361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/25\">",
"      Johanson M, Valli K, Revonsuo A, Wedlund JE. Content analysis of subjective experiences in partial epileptic seizures. Epilepsy Behav 2008; 12:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/26\">",
"      Coccaro EF, Posternak MA, Zimmerman M. Prevalence and features of intermittent explosive disorder in a clinical setting. J Clin Psychiatry 2005; 66:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/27\">",
"      Drake ME Jr, Hietter SA, Pakalnis A. EEG and evoked potentials in episodic-dyscontrol syndrome. Neuropsychobiology 1992; 26:125.",
"     </a>",
"    </li>",
"    <li>",
"     Poceta, JS, Mitler, MM. Sleep disorders: Diagnosis and treatment, Humana Press, Totowa, New Jersey 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/29\">",
"      Malow BA. Sleep and epilepsy. Neurol Clin 2005; 23:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/30\">",
"      Bisulli F, Vignatelli L, Naldi I, et al. Increased frequency of arousal parasomnias in families with nocturnal frontal lobe epilepsy: a common mechanism? Epilepsia 2010; 51:1852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/31\">",
"      Macleod S, Ferrie C, Zuberi SM. Symptoms of narcolepsy in children misinterpreted as epilepsy. Epileptic Disord 2005; 7:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/32\">",
"      Mihaescu M, Malow BA. Sleep disorders: a sometimes forgotten cause of nonepileptic spells. Epilepsy Behav 2003; 4:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/33\">",
"      Galimberti CA, Ossola M, Colnaghi S, Arbasino C. Focal epileptic seizures mimicking sleep paralysis. Epilepsy Behav 2009; 14:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/34\">",
"      Lugaresi E, Cirignotta F. Hypnogenic paroxysmal dystonia: epileptic seizure or a new syndrome? Sleep 1981; 4:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/35\">",
"      Derry CP, Duncan JS, Berkovic SF. Paroxysmal motor disorders of sleep: the clinical spectrum and differentiation from epilepsy. Epilepsia 2006; 47:1775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/36\">",
"      Provini F, Plazzi G, Lugaresi E. From nocturnal paroxysmal dystonia to nocturnal frontal lobe epilepsy. Clin Neurophysiol 2000; 111 Suppl 2:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/37\">",
"      Hening WA, Allen RP, Earley CJ, et al. An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep 2004; 27:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/38\">",
"      O'Keeffe ST. Restless legs syndrome. A review. Arch Intern Med 1996; 156:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/39\">",
"      Tinuper P, Provini F, Bisulli F, Lugaresi E. Hyperkinetic manifestations in nocturnal frontal lobe epilepsy. Semeiological features and physiopathological hypothesis. Neurol Sci 2005; 26 Suppl 3:s210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/40\">",
"      Walters AS. Clinical identification of the simple sleep-related movement disorders. Chest 2007; 131:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/41\">",
"      Anderson KN, Smith IE, Shneerson JM. Rhythmic movement disorder (head banging) in an adult during rapid eye movement sleep. Mov Disord 2006; 21:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/42\">",
"      Hashizume Y, Yoshijima H, Uchimura N, Maeda H. Case of head banging that continued to adolescence. Psychiatry Clin Neurosci 2002; 56:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/43\">",
"      Derry CP, Davey M, Johns M, et al. Distinguishing sleep disorders from seizures: diagnosing bumps in the night. Arch Neurol 2006; 63:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/44\">",
"      Manni R, Terzaghi M, Repetto A. The FLEP scale in diagnosing nocturnal frontal lobe epilepsy, NREM and REM parasomnias: data from a tertiary sleep and epilepsy unit. Epilepsia 2008; 49:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/45\">",
"      M&uuml;ller J, Wissel J, Masuhr F, et al. Clinical characteristics of the geste antagoniste in cervical dystonia. J Neurol 2001; 248:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/46\">",
"      Demirkiran M, Jankovic J. Paroxysmal dyskinesias: clinical features and classification. Ann Neurol 1995; 38:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/47\">",
"      Bruno MK, Hallett M, Gwinn-Hardy K, et al. Clinical evaluation of idiopathic paroxysmal kinesigenic dyskinesia: new diagnostic criteria. Neurology 2004; 63:2280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/48\">",
"      Lotze T, Jankovic J. Paroxysmal kinesigenic dyskinesias. Semin Pediatr Neurol 2003; 10:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/49\">",
"      Bhatia KP. The paroxysmal dyskinesias. J Neurol 1999; 246:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/50\">",
"      Sethi NK, Labar D, Torgovnick J. Myoclonic epilepsy masquerading as a tic disorder. Clin Neurol Neurosurg 2007; 109:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/51\">",
"      Mahone EM, Bridges D, Prahme C, Singer HS. Repetitive arm and hand movements (complex motor stereotypies) in children. J Pediatr 2004; 145:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/52\">",
"      Tan NC, Chan LL, Tan EK. Hemifacial spasm and involuntary facial movements. QJM 2002; 95:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/53\">",
"      Port JD. Advanced magnetic resonance imaging techniques for patients with hemifacial spasm. Ophthal Plast Reconstr Surg 2002; 18:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/54\">",
"      Defazio G, Abbruzzese G, Girlanda P, et al. Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study. Arch Neurol 2002; 59:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/55\">",
"      Hallett M. Blepharospasm: recent advances. Neurology 2002; 59:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/56\">",
"      Towfigh A, Mostofi N, Motamedi GK. Poststroke partial seizures presenting as hemifacial spasm. Mov Disord 2007; 22:1981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/57\">",
"      Arzimanoglou AA, Salefranque F, Gouti&egrave;res F, Aicardi J. Hemifacial spasm or subcortical epilepsy? Epileptic Disord 1999; 1:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/58\">",
"      Espay AJ, Schmithorst VJ, Szaflarski JP. Chronic isolated hemifacial spasm as a manifestation of epilepsia partialis continua. Epilepsy Behav 2008; 12:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/59\">",
"      Armon C, McEvoy KM, Westmoreland BF, McManis PG. Clinical neurophysiologic studies in stiff-man syndrome: use of simultaneous video-electroencephalographic-surface electromyographic recording. Mayo Clin Proc 1990; 65:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/60\">",
"      Syvertsen M, Helde G, Stovner LJ, Brodtkorb E. Headaches add to the burden of epilepsy. J Headache Pain 2007; 8:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/61\">",
"      Menon B. Symptomatic occipital epilepsy misdiagnosed as migraine. Headache 2007; 47:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/62\">",
"      Panayiotopoulos CP. Elementary visual hallucinations, blindness, and headache in idiopathic occipital epilepsy: differentiation from migraine. J Neurol Neurosurg Psychiatry 1999; 66:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/63\">",
"      Panayiotopoulos CP. Visual phenomena and headache in occipital epilepsy: a review, a systematic study and differentiation from migraine. Epileptic Disord 1999; 1:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/64\">",
"      Andermann F, Zifkin B. The benign occipital epilepsies of childhood: an overview of the idiopathic syndromes and of the relationship to migraine. Epilepsia 1998; 39 Suppl 4:S9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/65\">",
"      Ito M, Adachi N, Nakamura F, et al. Characteristics of postictal headache in patients with partial epilepsy. Cephalalgia 2004; 24:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/66\">",
"      Leniger T, Isbruch K, von den Driesch S, et al. Seizure-associated headache in epilepsy. Epilepsia 2001; 42:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/67\">",
"      Yankovsky AE, Andermann F, Bernasconi A. Characteristics of headache associated with intractable partial epilepsy. Epilepsia 2005; 46:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/68\">",
"      F&ouml;rderreuther S, Henkel A, Noachtar S, Straube A. Headache associated with epileptic seizures: epidemiology and clinical characteristics. Headache 2002; 42:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/69\">",
"      Cai S, Hamiwka LD, Wirrell EC. Peri-ictal headache in children: prevalence and character. Pediatr Neurol 2008; 39:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/70\">",
"      Fanella M, Fattouch J, Casciato S, et al. Ictal epileptic headache as \"subtle\" symptom in generalized idiopathic epilepsy. Epilepsia 2012; 53:e67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/71\">",
"      Russell MB, Olesen J. A nosographic analysis of the migraine aura in a general population. Brain 1996; 119 ( Pt 2):355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/72\">",
"      Rubin D, McAbee GN, Feldman-Winter LB. Auditory hallucinations associated with migraine. Headache 2002; 42:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/73\">",
"      Florindo I, Bisulli F, Pittau F, et al. Lateralizing value of the auditory aura in partial seizures. Epilepsia 2006; 47 Suppl 5:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/74\">",
"      Korsnes MS, Hugdahl K, Nyg&aring;rd M, Bj&oslash;rnaes H. An fMRI study of auditory hallucinations in patients with epilepsy. Epilepsia 2010; 51:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/75\">",
"      Krabbendam L, van Os J. Schizophrenia and urbanicity: a major environmental influence--conditional on genetic risk. Schizophr Bull 2005; 31:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/76\">",
"      Bianchi MT, Dworetzky BA, Bromfield EB. Auditory auras in patients with postencephalitic epilepsy: case series. Epilepsy Behav 2009; 14:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/77\">",
"      Hurst RW, Lee SI. Ictal tinnitus. Epilepsia 1986; 27:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/78\">",
"      Bisulli F, Tinuper P, Avoni P, et al. Idiopathic partial epilepsy with auditory features (IPEAF): a clinical and genetic study of 53 sporadic cases. Brain 2004; 127:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/79\">",
"      Ohayon MM. Prevalence of hallucinations and their pathological associations in the general population. Psychiatry Res 2000; 97:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/80\">",
"      Widdess-Walsh P, Kotagal P, Jeha L, et al. Multiple auras: clinical significance and pathophysiology. Neurology 2007; 69:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/81\">",
"      Lennox, WG, Cobb, S. Aura in epilepsy: a statistical review of 1359 cases. Arch Neurol Psychiatry 1933; 30:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/82\">",
"      Shergill SS, Cameron LA, Brammer MJ, et al. Modality specific neural correlates of auditory and somatic hallucinations. J Neurol Neurosurg Psychiatry 2001; 71:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/83\">",
"      Honig A, Romme MA, Ensink BJ, et al. Auditory hallucinations: a comparison between patients and nonpatients. J Nerv Ment Dis 1998; 186:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/84\">",
"      Choong C, Hunter MD, Woodruff PW. Auditory hallucinations in those populations that do not suffer from schizophrenia. Curr Psychiatry Rep 2007; 9:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/85\">",
"      Dauvilliers Y, Billiard M, Montplaisir J. Clinical aspects and pathophysiology of narcolepsy. Clin Neurophysiol 2003; 114:2000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/86\">",
"      Assal F, Cummings JL. Neuropsychiatric symptoms in the dementias. Curr Opin Neurol 2002; 15:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/87\">",
"      F&eacute;nelon G, Thobois S, Bonnet AM, et al. Tactile hallucinations in Parkinson's disease. J Neurol 2002; 249:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/88\">",
"      Tousi B, Frankel M. Olfactory and visual hallucinations in Parkinson's disease. Parkinsonism Relat Disord 2004; 10:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/89\">",
"      Bannier S, Berdagu&eacute; JL, Rieu I, et al. Prevalence and phenomenology of olfactory hallucinations in Parkinson's disease. J Neurol Neurosurg Psychiatry 2012; 83:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/90\">",
"      Brady KT, Lydiard RB, Malcolm R, Ballenger JC. Cocaine-induced psychosis. J Clin Psychiatry 1991; 52:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/91\">",
"      Evers S, Ellger T. The clinical spectrum of musical hallucinations. J Neurol Sci 2004; 227:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/92\">",
"      Balasubramaniam B, Park GR. Sexual hallucinations during and after sedation and anaesthesia. Anaesthesia 2003; 58:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/41/18074/abstract/93\">",
"      Webster R, Holroyd S. Prevalence of psychotic symptoms in delirium. Psychosomatics 2000; 41:519.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2230 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-217.117.136.88-094BD8D684-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_41_18074=[""].join("\n");
var outline_f17_41_18074=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SYNCOPE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PSYCHOLOGICAL DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Psychogenic nonepileptic seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Panic attacks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Episodic dyscontrol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SLEEP DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Specific disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Narcolepsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Nocturnal paroxysmal dystonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Periodic limb movements of sleep and restless legs syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Sleep starts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Rhythmic movement disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Sleep walking and night terrors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      MOVEMENT DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Paroxysmal dyskinesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Tics and stereotypies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Hemifacial spasm, blepharospasm, and Meige syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Stiff-person syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      MIGRAINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      HALLUCINATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Somatosensory hallucinations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Visual hallucinations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Auditory hallucinations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Olfactory hallucinations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Etiologies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      OTHERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/2230\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/2230|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/38/32364\" title=\"table 1\">",
"      Differential diagnosis of seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/53/5980\" title=\"table 2\">",
"      Clinical features of psychogenic nonepileptic seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/49/24349\" title=\"table 3\">",
"      Disorders causing visual hallucinations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/58/30635\" title=\"table 4\">",
"      Visual hallu drugs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/1/36889?source=related_link\">",
"      Acute toxic-metabolic encephalopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36361?source=related_link\">",
"      Ambulatory monitoring in the assessment of cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13801?source=related_link\">",
"      Anatomy and etiology of taste and smell disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/36/42569?source=related_link\">",
"      Approach to the patient with visual hallucinations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/44/44743?source=related_link\">",
"      Basilar-type migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/60/970?source=related_link\">",
"      Classification and evaluation of dystonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7689?source=related_link\">",
"      Classification and evaluation of myoclonus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25913?source=related_link\">",
"      Clinical features and diagnosis of narcolepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=related_link\">",
"      Diagnosis of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18682?source=related_link\">",
"      Evaluation of syncope in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25753?source=related_link\">",
"      Evaluation of the first seizure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18058?source=related_link\">",
"      Hyperkinetic movement disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/30/15849?source=related_link\">",
"      Juvenile myoclonic epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/1/23578?source=related_link\">",
"      Localization-related (partial) epilepsy: Causes and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/41/12951?source=related_link\">",
"      Mechanisms, causes, and evaluation of orthostatic and postprandial hypotension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4711?source=related_link\">",
"      Nocturnal leg cramps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29175?source=related_link\">",
"      Nonepileptic paroxysmal disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24376?source=related_link\">",
"      Nonepileptic paroxysmal disorders in infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5272?source=related_link\">",
"      Pathogenesis and etiology of syncope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7305?source=related_link\">",
"      Pharmacotherapy for panic disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33226?source=related_link\">",
"      Psychogenic nonepileptic seizures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=related_link\">",
"      Reflex syncope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32554?source=related_link\">",
"      Restless legs syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40841?source=related_link\">",
"      Seizures and epilepsy in the elderly patient: Etiology, clinical presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/41/665?source=related_link\">",
"      Stiff-person syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1128?source=related_link\">",
"      Sudden unexpected death in epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22664?source=related_link\">",
"      Tourette syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6537?source=related_link\">",
"      Treatment of myoclonus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15368?source=related_link\">",
"      Video and ambulatory EEG monitoring in the diagnosis of seizures and epilepsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_41_18075="Identifying asthmatic patients";
var content_f17_41_18075=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73952&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73952&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Approaches for identifying persons with asthma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Method",
"       </td>",
"       <td class=\"subtitle1\">",
"        Problems",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clinical evaluation",
"       </td>",
"       <td>",
"        Nonstandardization of physician criteria for diagnosis; bias toward more severe cases; bias by access to physician",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Questionnaire history of diagnosis",
"       </td>",
"       <td>",
"        Same as above; plus recall bias in subjects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Questionnaire history of symptoms",
"       </td>",
"       <td>",
"        Possibly influenced by frequency of other symptoms; less specific than physician's diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Response to bronchodilator",
"       </td>",
"       <td>",
"        May be influenced by level of FEV",
"        <sub>",
"         1",
"        </sub>",
"        correlation with bronchodilator; may lack sensitivity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bronchoconstrictor response",
"       </td>",
"       <td>",
"        Influenced by level of FEV",
"        <sub>",
"         1",
"        </sub>",
"        ; may be nonspecific",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     : forced expiratory volume in one second.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Weiss ST, Speizer FE. Epidemiology and natural history. In: Bronchial Asthma: Mechanisms and Therapeutics, 3rd ed, Weiss EB, Stein M (Eds), Little, Brown, Boston 1993.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_41_18075=[""].join("\n");
var outline_f17_41_18075=null;
var title_f17_41_18076="Clinical summary cardioversion";
var content_f17_41_18076=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical summary: Synchronized cardioversion",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        1. Assess patient:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Perform cardioversion immediately in hemodynamically unstable patients and those with altered mental status (lethargic, agitated).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &bull; Administer supplemental oxygen and intravenous sedation and analgesia to stable patients undergoing cardioversion.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Turn the machine on.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Attach ECG leads to stable patients.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Select the lead that displays the tallest R wave.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Set machine to synchronous mode.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Apply electrode conduction paste or gel to the paddles or open the electrode pads.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. Apply paddles or pad to appropriate positions on chest (anterior pad or paddle to right of sternum just under the clavicle, apex pad or paddle in the midaxillary line at the level of the nipple). Paddles must be applied firmly*.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8. Select an initial energy dose of 0.5 to 1 Joules/kg.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9. Charge unit by simultaneously pressing the charge button on the paddles or by pressing the charge button on the machine if electrode pads are being used.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10. Ensure all personnel are clear from the patient and the patient's stretcher by loudly stating \"All Clear!\" prior to shock delivery.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11. Deliver current by either depressing discharge buttons simultaneously on the paddles or by pressing the discharge button on the machines if electrode pads are being used.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12. Assess clinical and electrical response to shock delivery.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        13. Proceed according to pediatric advanced life support guidelines.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Anterior/posterior paddle position is acceptable but less practical during a critical resuscitation.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Scarfone RJ, Cho CS. Cardioversion and Defibrillation. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_41_18076=[""].join("\n");
var outline_f17_41_18076=null;
var title_f17_41_18077="RE digestion of PCR product";
var content_f17_41_18077=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F81760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F81760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Restriction enzyme digestion products",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 421px; height: 333px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This representation of an agarose gel shows how restriction enzyme digestion can be used to distinguish between an individual who is homozygous for a normal version of a gene versus individuals homozygous or heterozygous for a mutation in that gene. In this case the mutation creates a new restriction enzyme site. The normal piece of DNA is 200 base pairs long and lacks the restriction enzyme site, so it is not cut by the enzyme. The DNA with the mutation has the restriction enzyme sit, so it is cut into two pieces of 180 and 20 base pairs.",
"    <br>",
"     Lane 2: Individual with the normal gene; only the 200 base pair DNA is seen.",
"     <br>",
"      Lane 3: Individual heterozygous for the mutation; the normal 200 base pair DNA and the 180 and 20 base pair pieces are seen.",
"      <br>",
"       Lane 4: Individual heterozygous for the mutation; only the 180 and 20 base pair pieces are seen.",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_41_18077=[""].join("\n");
var outline_f17_41_18077=null;
var title_f17_41_18078="HT dementia WHIMS";
var content_f17_41_18078=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F57042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F57042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 497px\">",
"   <div class=\"ttl\">",
"    Risk of dementia with combined estrogen-progestin therapy versus placebo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 477px; height: 449px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the Women's Health Initiative Memory Study, after a mean follow-up of four years, HT was associated with an increased risk of dementia (overall hazard ratio [HR] 2.05, 95% CI 1.21-3.48). Data shown only through five years of follow-up because numbers at risk are too small after this point for precise estimates.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Shumaker SA, Legault C, Thal L, et al. Estrogen plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women's Health Initiative Memory Study: A Randomized Controlled Trial. JAMA 2003; 289:2651.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_41_18078=[""].join("\n");
var outline_f17_41_18078=null;
var title_f17_41_18079="Lung cancer extension MRI II";
var content_f17_41_18079=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F65039&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F65039&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transdiaphragmatic extension of lung carcinoma on MRI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 357px; height: 285px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sagittal T2-weighted section shows transdiaphragmatic extension of the lesion (long arrow). There is also a posterior pleural effusion (short arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_41_18079=[""].join("\n");
var outline_f17_41_18079=null;
